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The conditions and mechanisms that produce decrements in exercise performance 
have been an important area of research for decades. However, the sensation of fatigue 
that may persist for hours or days after exercise has received less attention. This long-
lasting fatigue sensation is common in clinical populations. In chronic fatigue syndrome 
(CFS), moderate physical activity can produce increased fatigue sensations that last for 
several days. A recent study of CFS patients demonstrated significant increases in fatigue 
and pain sensations that were closely related to gene expression changes in metabolite-
detecting, adrenergic, and immune markers following 25 minutes of moderate, whole 
body exercise. This exercise stimulus did not produce long-lasting fatigue or changes in 
gene expression in healthy age and gender-matched controls.  
 The graded exercise test (GXT) is commonly applied in CFS research. Although 
intense, the GXT rarely produces long-lasting fatigue in healthy individuals and its effect 
on CFS patients’ postexertional fatigue is unclear.  Thus, the goals of these studies were 
to examine gene expression and fatigue sensations in healthy, trained individuals during 
and after three different exercise stressors: a GXT, a 40k time trial in ambient conditions 
(AT), and the same time trial in adverse, hot conditions (HT).  It was hypothesized that 
there would be larger changes in gene expression following both AT and HT, compared 
to GXT.   The first study explored the differences in gene expression following GXT and 
AT.  Following AT, there were larger decreases in metabolite-detecting mRNA, larger 
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increases in adrenergic, immunologic, and serotonin mRNA as compared to GXT. 
Further, these gene expression changes were different from postexercise responses of 
CFS patients. The goal of the second study was to add an additional stressor to the 40k 
time trial – heat.  Because TRPV receptors are sensitive to heat, it was thought that the 
heat stress would cause larger increases in TRPV mRNA.  However, because exercise 
power was reduced during HT, there were no differences in gene expression between the 
two trials except that IL6 mRNA decreased significantly more following AT compared to 
HT.  Collectively, these results show that gene expression in healthy individuals is 
affected by the intensity and length of the exercise.  The decreases in metabolite-
detecting mRNA are thought to be an attempt to restore homeostasis in the fatigue and 
pain detecting receptors.  The fact that there was no difference between AT and HT 
suggests that heat is an additional metabolite that activates the metabolite-detecting 
receptors, helping to regulate the intensity of exercise and the amount of fatigue during 
exercise.  Adrenergic receptors increased, possibly causing a decrease in blood flow 
following exercise and increasing the resting levels of metabolites and subsequently 
increasing the resting fatigue signal.  The change in the ratio of serotonin/dopamine may 
also contribute to the increased fatigue sensation following exercise. 
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Muscle fatigue, from a physiological perspective, has been defined as any 
reduction in force-generating capacity of a muscle (24, 26).  In the early 1900s, Mosso 
recognized three different possible causes of muscle fatigue that limited exercise 
performance: peripheral, central, and cognitive (51).   Since Mosso described these three 
types of fatigue, researchers have attempted to determine the primary factors that limit 
exercise performance.  In 1984, Bigland-Ritchie identified eight possible sites of muscle 
fatigue, including 1) excitatory input to higher motor centers, 2) excitatory drive to lower 
motor neurons, 3) motor neuron excitability, 4) neuromuscular transmission, 5) 
sarcolemma excitability, 6) excitation-contraction coupling, 7) contractile mechanisms, 
and 8) metabolic energy supply and metabolite accumulation (Figure 1.1) (12).  These 
sites split nicely into two categories: central (1-3) and peripheral (4-8), but it seems that 
Mosso’s idea of a separate category for cognitive, or mental, causes was ignored.  For 
years, researchers have attempted to identify the main factor(s) responsible for muscle 
fatigue and hence the limitations to exercise performance.  These arguments have 
generally been divided among those focused on a peripheral cause of fatigue versus a 
centrally mediated cause of fatigue (5, 22, 23, 39, 41, 49, 50, 54, 67). 
 
Peripheral Causes of Muscle Fatigue 
Peripheral mechanisms of fatigue are defined as factors that influence force 
production at the neuromuscular junction or within the muscle and may involve action 
potential failure, excitation-contraction coupling failure, or impairment in crossbridge 
cycling in the presence of unchanged or increased neural drive (62).  Several factors 
within the muscle influence the force production capability.  For years, it was thought 
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that the accumulation of metabolic byproducts limited energy production in the muscles 
and was the primary cause of fatigue.  The accumulation of lactate was thought to be a 
major factor that limited muscle performance due to the belief that dissociated hydrogen 
ions reduced local pH to levels incompatible with muscle contraction (40, 42).  However, 
this idea has largely been refuted, as lactate is a substrate that is quickly utilized by other 
tissues (16, 17).  Further, at physiologic temperatures, the reduced pH during heavy 
exercise does not have a direct effect on contractility and fatigability (60, 63, 65, 66).  
Another metabolite, inorganic phosphate (Pi), may play a more substantial role in 
producing peripheral fatigue.  There is evidence that Pi, which is released during intense 
exercise, may reduce crossbridge force production, inhibit sarcoplasmic Ca2+ reuptake, 
and reduce the amount of free Ca2+ available for release.  All of these factors could be 
involved in increased muscle fatigue (65, 66).  Recent advances in knowledge of Ca2+ 
handling in muscle supports this idea.  For example, the ryanodine receptor located on the 
sarcoplasmic reticulum may play a major role in regulating Ca2+ release during exercise.  
Exercise causes remodeling of the ryanodine receptor by protein kinase A 
hyperphosphorylation, resulting in “leaky” calcium channels.  In turn, this results in 
decreased  Ca2+ reuptake and a subsequent decrease in exercise capacity (7, 8).   
Coincident with the decrease in force production, there are subjective correlates 
that exercisers experience as peripheral fatigue.  These include muscular sensations that 
have been described as pain, burning, heaviness, and the like.  Interestingly, the 
misguided belief that these sensations are caused by the accumulation of lactic acid or 




Central Mechanisms of Muscle Fatigue 
Central mechanisms of muscle fatigue are defined as mechanisms that cause a 
reduction in neural drive to the muscle, resulting in a decline in force production 
independent of changes in skeletal muscle contractility (62). The sites that may affect 
neural drive, using Bigland-Ritchie’s nomenclature, include excitatory input to higher 
motor centers, excitatory drive to lower motor neurons, and motor neuron excitability 
(12). Because direct measurement of central processes is difficult at best, and in some 
cases impossible in humans, this area of research was largely ignored until recently.  
Even today, our understanding of the central nervous system’s (CNS) role in fatigue is 
limited. To further complicate this aspect of fatigue, researchers have recognized that the 
role of central processes in producing fatigue varies greatly with the type of exercise 
performed, e.g. maximal vs. submaximal or sustained vs. intermittent (19, 38). 
There are numerous ways in which central fatigue has been observed. Classically, 
central fatigue is demonstrated when maximal voluntary force can be augmented with a 
superimposed electrical stimulation of the muscle or nerve, thus showing a decrement in 
neural drive (6, 13). However, determining the cause of this decrement has proved to be 
more difficult.  Central drive has both conscious and unconscious elements.  Conscious 
elements include concepts such as motivation and effort that are problematic for 
physiologists to manipulate and measure.  The unconscious elements include the sum of 
inhibitory and excitatory influences acting on the motor neurons, the motor cortex, and 




Similar to peripheral fatigue, it has been hypothesized that central fatigue may be 
influenced by “metabolites” produced from increased CNS demands during heavy or 
prolonged exercise.  Thus, central fatigue may be due to the accumulation of metabolites 
such as serotonin and ammonia with concurrent decreases in dopamine and acetylcholine 
in the brain (58, 62).  These changes may impair the ability of the brain to maintain or 
increase neural drive, resulting in decrements in muscle force (62).  
Consistent with the idea that increased CNS demands may limit neural drive, it is 
possible that inadequate delivery of substrates to the brain produces central fatigue.  
There is some evidence that during strenuous exercise, cerebral blood flow [20, 21] is 
inadequate to key brain areas, resulting in decreased oxygenation and glucose availability 
(57). Either or both of these conditions have the potential to negatively impact neural 
drive and thus muscle force.   Decreased glucose metabolism or availability within the 
brain could also impair conscious aspects of neural drive, decreasing central motor output 
(10, 11, 44).  The neurotransmitter serotonin is also implicated in fatigue.  An increase in 
systemic tryptophan leads to an increase in serotonin in the brain (53) activating the 5-HT 
receptor, which causes an increase in central fatigue (68). 
Evidence also suggests that hyperthermia plays an important role in central 
fatigue.  When brain, and more specifically, hypothalamic temperature increases, it is 
found that there is a decrease in both force output and central command (31, 55). 
However, this mechanism is probably only related to whole body exercise in which core 
temperature increases are common and is not a key factor underlying force decrements 
during isolated muscle activity. 
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As in peripheral fatigue, central fatigue is associated with several perceptual 
changes. As motor command increases in order to sustain a given force, the perception of 
effort also increases. Aspects of conscious awareness of fatigue are also present and will 
be discussed in more detail below. 
 
Integrated Model of Muscle Fatigue 
Originally, researchers primarily focused on fatigue mechanisms in the muscle.  
More recently, researchers began to focus on central mechanisms – or mechanisms 
involving corticospinal or higher brain centers.  A number of researchers suggest that 
reduced central neural drive may be a result of inhibitory influences from muscle and/or 
other peripheral organs, thus integrating the central and peripheral models of fatigue.  
Decreases in central motor output during moderate exercise may be due to increases in 
afferent feedback from the Group III and IV afferent nerve fibers due to metabolic 
changes in the periphery (1, 27).  Several recent studies have provided evidence to 
support this integrated model.  When hypoxia is induced during exercise, causing an 
increase in metabolic by-products (15% O2), there is a decrease in central motor drive as 
measured by iEMG, which suggests an increase in central fatigue as compared to 
normoxia (3).  Further, there is a decrease in iEMG following a prefatiguing exercise, 
meaning that there is increased afferent feedback with more fatigue, perhaps limiting the 
degree of peripheral fatigue during an exercise bout (2).  Another study attempted to 
examine whether feedback from the Group IV afferents was the primary contributor to 
central fatigue.  This study used fentanyl, an opioid receptor antagonist, to selectively 
block the Group IV afferent response.  It was found that the central motor drive was 
7 
 
increased throughout the subsequent exercise trial as a result of decreased afferent 
feedback to the central command center.  Thus, central fatigue was substantially 
decreased while peripheral fatigue was greatly increased (4).  These data suggest that 
afferent feedback plays a role in increasing central fatigue.  The activation of these 
afferent nerve fibers by metabolites will be discussed in a subsequent paragraph. 
An aspect of central fatigue that is important to evaluate is the cognitive 
perception of fatigue, or the perception of “feeling tired”.  Intense or sustained physical 
activity may alter the activity of brain neural networks, which in turn produces a 
conscious awareness of those alterations (61).  The sensation of fatigue may arise from 
anatomical brain structures associated with conscious perception.  These may include the 
motor and premotor complex, supplementary motor complex, basal ganglia, insula, 
anterior cingulate, and the cerebellum (61).  The integration of the sensation of fatigue 
via the Group III and IV afferents may also occur in the brain stem or spinal cord (36, 
59).  Within the spinal cord, afferent neurons may activate inhibitory interneurons (14, 
21, 30) or activate the spinal cord, signaling that the perfusion of the exercising muscle 
was inadequate to meet metabolic demand.  Finally, afferent neurons may provide input 
to the brainstem, posterior hypothalamus, or midbrain, which in turn influence central 
command for autonomic and ventilatory output (36, 37).  All of these factors may also 
contribute to the cognitive perception of fatigue. 
Afferent feedback, from metabolite accumulation, substrate depletion, or cardiac 
and respiratory limitations, not only influences central motor drive but may also influence 
the cognitive perception of fatigue (18, 56, 61, 64).  Motivational and psychological 
factors likely determine the degree to which the individual responds to sensations of 
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fatigue (61).  When low motivation exists, the person doing the exercise may have an 
increased sensation of fatigue and a subsequent decrease in performance.   
The integrated model of fatigue works through afferent nerve fibers in the 
periphery, sending signals to the central command center, which play a role in 
modulating the amount of fatigue.  One of the questions that arise is what causes this 
increased afferent nerve activity with an increase in exercise intensity or duration.  An in 
vitro study by Light and colleagues, using calcium imaging of mouse dorsal root ganglion 
neurons (DRGs), found that there were two classes of receptors on these cells.  These 
receptors responded to low and high doses of metabolites that correspond with moderate 
and high intensity exercise and may signal for fatigue and pain, respectively (46).  The 
metabolites to which these cells respond included a combination of increased lactate, 
extracellular ATP, and hydrogen ions (decreased pH).   
There are several receptors on the afferent nerve endings that are sensitive to 
these metabolites, including ASIC3 (acid-sensing ion channel), TRPV (transient receptor 
potential vanilloid channels), and P2X (purinergic receptor).  A combination of 
extracellular lactate and extracellular ATP increased the sensitivity of the ASIC3 
receptor, making it more receptive to changes in metabolites within the physiological 
realm (52) while blocking the ASIC3 receptor using amiloride found that the Group IV 
afferent response to lactate and contraction was blocked, suggesting that ASIC3 receptor 
activation is essential for sending a fatigue signal to the central command center (34).  
The ASIC3 receptor may form heteromers with ASIC2 allowing activation at different 
pH levels, sending signals to the central command center that may be perceived as fatigue 
or pain (33).  P2X receptors are also located on Group III and IV afferents that evoke the 
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exercise pressor reflex, which are the same afferent nerve fibers that are activated with 
central fatigue (35).  The effects of P2X receptors are attenuated in an environment that 
simulates exercise – decreased pH and increased temperature (28, 29) – perhaps 
suggesting that the P2X receptors do not play as large of a role in signaling as the ASIC3 
receptor or the TRP receptors.  However, activation of the P2X receptors by extracellular 
ATP may help sensitize the ASIC3 receptor to lactate, allowing the metaboreceptors to 
sense a subtle decrease in extracellular pH (15).  The TRPV1 and TRPV4 
metaboreceptors may also play a role in the afferent nerve signal to the brain.  These 
receptors are sensitive to an increase in acid, heat, and endocannaboids (9, 20).  TRP 
receptors are sensitive to temperatures ranging from approximately 23-50 degrees Celsius 
(9), allowing a modulation of the afferent signal to the brain depending on the change in 
temperature of the body.  Finally, the adrenergic β-receptors may enhance the metabolite 
signal on these afferents, especially in patients with fibromyalgia (48). 
 
Fatigue: Clinical Perspective 
From a clinical perspective, the symptom of “fatigue” is much broader than the 
physiological definition. Clinically, fatigue has been defined as “a subjective lack of 
physical and/or mental energy that is perceived by the individual or caregiver to interfere 
with usual and desired activities”(43).  This definition relies, in part, on assessing the 
perceptions of individuals or their caregivers and determining the impact of these 
perceptions on physical and cognitive function.  
In pathologic fatigue conditions, such as Chronic Fatigue Syndrome (CFS), 
evidence suggests that a dysregulation in afferent fatigue signaling may exist.  CFS has 
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been defined by the Centers of Disease Control (CDC) as “persistent and relapsing 
fatigue not relieved by rest that severely compromises activities of daily life for 6 months 
or longer, for which other possible medical causes have been ruled out” (25).  One of the 
main problems with CFS is that diagnosis relies on subjective perceptual responses. 
Objective biomarkers of fatigue would be extremely useful to diagnose CFS and to track 
responses to various therapeutic approaches.  A study by Light et al. in 2009 examined 
metabolic (ASIC3, P2X4 and P2X5, and TRPV1), immunologic (IL-6, IL-10, TNF-α, 
TLR4, CD14), and adrenergic (α-2a, β-1, β-2, COMT) gene expression in leukocytes and 
found an upregulation in the mRNA for all of the genes following 25 minutes of 
moderate (70% of age-predicted maximum heart rate) exercise in CFS patients as 
compared to healthy, age-matched control participants (45, 47).  It was also found that for 
subjective ratings of mental fatigue, physical fatigue, and pain (all on scales of 0-100 
with 0 being no fatigue and 100 being the worst fatigue imaginable), patients with CFS 
reported a significantly higher rating of fatigue and pain throughout the 48 hours while 
also showing significantly higher increases in pain and fatigue from baseline following 
the exercise than healthy controls (45, 47).  This paper suggested that an increase in the 
amount of P2X and ASIC3 mRNA following exercise may lead to an increase in the 
number of receptors and, subsequently, to an increased sensation of fatigue due to 
increased afferent nerve signal to the brain from even resting levels of metabolites (47).  
The study also suggested that the changes in mRNA in the leukocytes could increase the 
cytokines that sensitize muscle afferents, thus making them more sensitive to metabolites 
and increasing the sensation of fatigue following a bout of exercise (47). 
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The possible role of these biomarkers in objectively describing fatigue needs to be 
further elucidated.  Therefore, this dissertation will explore two different aspects of 
perceptual fatigue and these biomarkers to better understand how they are affected by 
exercise in healthy individuals.  The first paper will compare the responses of perceptual 
fatigue and biomarkers in trained cyclists following a high-intensity, short (graded 
exercise test) and long (40k time trial) exercise.  The second paper will compare the 
responses of these biomarkers in trained cyclists following a 40k time trial at room 
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Figure 1.1: Potential sites of fatigue as described by Bigland-Ritchie (1984): a, excitatory 
input to the motor cortex; b, excitatory drive to lower motoneuron; c, motoneuron 
excitability;  d, neuromuscular transmission; e, sarcolemma excitability; f, excitation-
contraction coupling; g, contractile mechanism; h, metabolic energy supply (32).  A-C 







 GENE EXPRESSION MARKERS OF FATIGUE AND  
 PAIN SENSATIONS: A COMPARISON 





 Metabolite-detecting afferents and adrenergic receptors have been linked to pre- 
and postexercise fatigue within Chronic Fatigue Syndrome (CFS).  It is unclear, however, 
whether these same pathways are altered during strenuous exercise in trained healthy 
subjects, and whether exercise duration or intensity more strongly influences gene 
expression.  Previous studies have used both graded exercise tests (GXT) and moderate 
intensity time trials to examine mRNA changes during postexercise fatigue with CFS.  
Twenty moderately trained cyclists performed a GXT (mean duration 10.9 min) and a 
40k time trial (TT, mean duration 74.3 min) on a bicycle ergometer.  Following each 
trial, blood lactates were measured one and five minutes postexercise and blood draws 
were performed 0.5, 8, 24, and 48 hours postexercise.  Leukocytes were separated for 
RNA extraction and qPCR analysis for gene expression (mRNA) of metabolite detecting, 
adrenergic, indolamine, and immune receptors.  Physical fatigue and pain were greater 
following TT (p˂0.05) but RPE and postexercise lactate were higher for GXT (<.008), 
indicating higher intensity.  Mean mRNA changes were significantly greater following 
TT vs GXT, including: 1) decreases in gene expression for metabolite-detecting ASIC1, 
ASIC3, P2X4, and TRPV1; 2) increases in adrenergic receptors α2a, α2c, β1, but 
decreases in β2; 3) increases in indolamine receptor HTR1D and decreases in DRD4; and 
4) increases in immune receptor IL-6 (p˂0.05).  These findings suggest that long 
duration, higher total workload exercise has more powerful effects on gene expression 






Traditionally, physiologists have viewed muscle fatigue as any exercise-induced 
decrement in maximal voluntary muscle force or power (8, 19).  Clinically, the symptom 
of fatigue includes the sensation of tiredness and greater effort during muscular 
contraction that can extend for a period of time beyond exercise.  In some clinical 
populations, fatigue is present at rest, manifested as decreased motivation, increased 
malaise, or even lack of mental focus (24, 49). 
Two interrelated aspects of fatigue, central and peripheral, ultimately limit 
physical performance and may also influence postexercise recovery.  Central fatigue, 
clinically defined, is “the failure to initiate and/or sustain attentional tasks and physical 
activities requiring self-motivation” (14, 15).  It is not clear which specific CNS 
structures inhibit central motor drive (CMD); however, peripheral factors can influence 
central fatigue via afferent feedback. In vitro experiments have shown dorsal root 
ganglion cells (Group IV afferents) containing the receptors ASIC3 (Acid-sensing Inward 
Current), P2X (purinergic) types 4 and 5, and TRPV1 (transient receptor potential 
vanilloid) respond to physiologic combinations of lactate, protons, and extracellular ATP 
(26).  These sensory receptors fall into two classes that encode for fatigue and/or pain 
based on metabolite concentrations (26). Thus, afferent feedback, in response to muscle 
metabolite accumulation, can inhibit CMD and also influence perceptual responses (12, 
41, 49, 52).  
Central and peripheral contributions to fatigue can be evaluated during maximal 
voluntary contraction by quantifying superimposed twitch characteristics and post-
contraction twitch potentiation via supra-maximal nerve stimulation (1-4).  In addition, 
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the sensation of fatigue and pain can be reliably assessed via a visual analog scale (VAS) 
during and after exercise (24, 25, 27, 54).  The perception of tiredness or heaviness may 
persist for several hours or days following exercise, even when there is no change in 
muscular function or performance (45).  In fact, Chronic Fatigue Syndrome (CFS) is, in 
part, defined by postexercise malaise (PEM) that interferes with normal physical and 
social functioning (18). 
In combination with the effects of metabolite-detecting receptors on afferent 
fibers, fatigue perception is influenced by sympathetic nervous system (SNS) effects on 
central and peripheral sensory pathways (27).  SNS effects on blood flow to working 
muscles can alter the local metabolite milieu, affecting peripheral afferent feedback (27).  
In CFS, researchers have shown alterations in leukocyte gene expression of adrenergic 
receptors, including α2a, α2c, β1, and β2 (22, 25, 27).   The immune system may also 
directly affect muscle afferents, making them more sensitive to metabolites (27).  
The neurotransmitters serotonin and dopamine have been implicated in fatigue (5, 
6, 31, 40).  Serotonin activates Group IV afferent fibers (51), increasing pain when 
injected intramuscularly (32).  When serotonin was augmented in rats by administering a 
5-HT agonist, exercise capacity decreased (5).  Decreases in dopamine can increase 
fatigue (31).  During exercise, dopamine metabolism is increased (10), decreasing levels 
of dopamine at exhaustion (5).  Increased serotonin (35) and a concurrent decrease in 
dopamine may decrease central motor drive (42, 50, 55).   
In efforts to identify objective markers of PEM, we examined mRNA expression 
of a group of molecular receptors involved in neuronal signaling of muscle fatigue and 
pain in CFS patients before and after exercise (25, 27, 54). Our exercise paradigm for 
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these studies was a 25 minute, moderate intensity (70% of age predicted maximal heart 
rate) combined arm and leg exercise, designed to resemble a typical daily activity. This 
paradigm resulted in significant increases in fatigue and pain sensations that persisted for 
up to 48 hours after exercise that were highly correlated to large changes in metabolite 
detecting, adrenergic, and immune receptor mRNAs.  Small or no changes in gene 
expression were observed in healthy controls who also reported no increases in 
postexercise fatigue or pain (25, 27, 54).  Other researchers have utilized a graded 
exercise test (GXT) to examine fatigue mechanisms in CFS (37, 43, 53), even though this 
type of exercise does not simulate activity that would likely be encountered by CFS 
patients.   
The purpose of this investigation was to examine perceptual fatigue and pain as 
well as gene expression markers of fatigue and pain in healthy cyclists before, during, 
and after two exercise modalities; a GXT and a 40k TT. The GXT was selected for this 
protocol because it is commonly utilized as a model in CFS research.  Although the GXT 
produces high metabolite levels in a short period of time, we predicted this exercise 
would not produce long-lasting fatigue and pain in healthy individuals.  It was 
hypothesized that the 40k time trial would elicit greater and longer-lasting increases in 
fatigue and pain sensations that would be reflected in changes in gene expression, 
although we did not know whether these changes would be in the same direction as we 
have previously observed in CFS. We also utilized objective indices of central and 
peripheral fatigue before and after exercise to determine whether these were related to 






  The experimental procedures used in this investigation were reviewed and 
approved by the University of Utah Institutional Review Board.  The procedures were 
explained verbally, and all participants provided written informed consent prior to 
testing.  Twenty healthy, moderately trained male (n=10) and female (n=10) cyclists 
between the ages of 18-55 were recruited for this investigation (mean ± SD; age 36.1 ± 
9.7 years, body weight 68.1 ± 9.2 kg, height 172.9 ± 6.3 cm, peak oxygen consumption 
(VO2peak) 54.8 ± 5.9 mL∙kg-1∙min-1).  Cyclists were excluded if any of the following 
applied: current, acute musculoskeletal injury; medications known to interfere with the 
sympathetic nervous system; unwillingness to comply with training interruptions 
mandated by the protocol; any uncontrolled chronic health condition.  
 
Protocol Overview 
Participants performed two tests, separated by at least one week: a graded 
exercise test to determine VO2peak and a 40k time trial on a Velotron cycle ergometer 
(Racermate, Seattle WA) that was adjusted to match each participant’s accustomed cycle 
position.  All participants refrained from exercise for 24 hours prior to the exercise test.  
Venous blood samples were obtained from the arm at baseline and at 0.5, 8, 24, and 48 
hours after each exercise test.  To assess the severity of preexisting and exercise-related 
fatigue and pain symptoms at the time of each blood draw, participants provided 
numerical ratings of mental fatigue, physical fatigue, and overall body pain or soreness 
using a 0-100 scale, where 0 was defined as no pain or fatigue and 100 was defined as the 
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greatest amount of fatigue or pain the participant could ever imagine.  Immediately after 
the baseline blood draw, participants began the exercise test as described below. 
 
GXT Protocol 
 Participants performed an incremental cycling test (VO2peak) beginning at 100W 
(50W for females) with resistance increasing 25W every minute until volitional 
exhaustion.  Participants pedaled at their preferred pedaling rate and the test was 
terminated when the cadence dropped more than 10 rpm for more than 5 seconds despite 
strong verbal encouragement.  Metabolic data were collected using open circuit 
calorimetry (Parvomedics, True Max 2400, Sandy, UT).  Peak oxygen consumption 
(VO2peak) was recorded as the highest VO2 measured in a 15-second period. 
 
40k Time Trial 
 On the second experimental day, participants performed a 40k time trial with 
instructions to cover the distance as fast as possible.  Following a 10-15 minute self-
selected warm-up, the participant began the test.  The participants were able to fully 
control the gearing of the Velotron and were able to monitor speed, power, distance 
covered, and cadence.  Heart rate, rating of perceived exertion (RPE), and work rate were 
recorded every 2.5 kilometers.  Upon completion of the test, participants were 







 A subset of participants (n=11; mean ± SD; age 41.5 ± 11.2 years, body weight 
66.4 ± 8.2 kg, height 174.8 ± 11.2 cm, VO2peak 50.3 ± 7.7 mL∙kg-1∙min-1) completed a 
separate, follow-up study to examine central and peripheral contributions to muscle 
fatigue 5-10 minutes before and 2 minutes after each exercise test (GXT and TT).  
Supramaximal magnetic stimulation of the femoral nerve was superimposed on and 
applied 5 seconds after a series of maximal voluntary contractions (MVCs) of the 
quadriceps.  
Participants sat in a semireclined position on a table, with the upper body 
supported by their elbows and a Pilates mini ball positioned under the lower back.  Each 
participant’s leg was marked with indelible ink and aligned with a mark on the table to 
assure proper positioning, with the knee joint angle set at 90° of flexion.  A magnetic 
stimulator (Magstim 2002; Wales, UK) connected to a 70mm double coil was used to 
stimulate the femoral nerve.  After the coil position that elicited the maximal quadriceps 
response was located, it was marked to ensure consistent coil placement for postexercise 
assessments.  The evoked quadriceps twitch force was obtained from a calibrated load 
cell (MLP-300; Transducer Techniques, Rio Nedo Temecula, CA) connected to a 
noncompliant strap, which was placed around the subject’s right leg, just superior to the 
malleoli.   
To verify that maximal magnetic stimuli were delivered, unpotentiated quadriceps 
single twitch forces (Qtw) were obtained every 30 seconds at 70, 80, 85, 90, 95, and 
100% of maximal stimulator output.  A plateau in baseline Qtw and M-wave amplitudes 
with increasing stimulus intensities was observed in every subject. The increase in Qtw 
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from 90% to 95% of the stimulator output was 1.2 ± 3.2% (P = .22) and from 95% to 
100% was -.08 ± 3.3% (P = .91).  The stimulator was set at 100% for all subjects and 
trials.   
We measured superimposed twitch force during and potentiated Qtw (Qtw,pot) 
force 5 seconds after a 5-second maximal isometric voluntary contraction of the 
quadriceps and repeated this procedure six times.    Peak force, maximal rate of force 
development (MRFD), maximal rate of relaxation (MRR), contraction time (CT), and 
reaction time (RT0.5) were analyzed for all Qtw,pot.  Voluntary activation of the quadriceps 
during the MVCs was assessed using a superimposed twitch technique (33).  Briefly, 
voluntary muscle activation compares the additional force produced during a single 
twitch superimposed on the MVC with the force produced by the potentiated single 
twitch delivered 5 seconds after MVC (1-(superimposed twitch force/Qtw.pot force)*100).  
 
Blood Sample Processing 
 Blood samples obtained at baseline and 0.5, 8, 24, and 48 hours after each time 
trial were collected in EDTA tubes.  Within 5 minutes of blood collection, the blood was 
centrifuged at 4100rpm (2.6rcf, Eppendorf Centrifuge 5702R) for 12 minutes.  
Immediately after, the white cell layer was carefully collected and stored in RLT + β-Me 
(Qiagen, Valencia, CA, USA) before being quickly frozen using a methanol-dry ice 
slurry and stored at -80°C.  RNA was extracted using RNeasy kits (Qiagen) according to 
manufacturer’s directions, and treated with RNase-free DNase-I (Qiagen).  Immediately 
following extraction, RNA was converted to a cDNA library using the ABI High 
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Capacity cDNA Archive kit (Applied Biosystems, Inc., Foster City, CA, USA).  The 
cDNA was stored at -20°C until analysis. 
The cDNA libraries were analyzed using the ABI quantitative, real-time PCR 
system on the ABI Prism 7900 Sequence Detection System (Applied Biosystems, Inc.) 
using ABI Taqman Master Mix (Applied Biosystems, Inc.).  Master mix/primer probe 
solutions were separately loaded onto 96-well preplates, with robot loading mixing these 
solutions when placed into 384 plates.  Plates were centrifuged to remove air bubbles 
from the wells.  Each sample was run in duplicate with the standards run in 
quadruplicate.  No-template control samples were also run to examine for contamination.  
Each 384-well plate contained eight samples and all genes were analyzed on the same 
plate.  Primer probes (all from Taqman Gene Expression Assays; Applied Biosystems, 
Inc.) were as follows; 
Adrenergic A2A (α-2A) – HS00265081_s1; Adrenergic A2C (α-2C) - HS03044628_s1; 
Adrenergic B-1 - Hs02330048_s1; Adrenergic B-2 - Hs00240532_s1; ASIC1 - 
Hs00241630_m1; ASIC3 - Hs00245097_m1; CREB1 - Hs00231713_m1; DRD4 - 
Hs00609526_m1; HTR1D - Hs00704742_s1; IL10 - Hs00174086_m1; IL6 - 
Hs00174131_m1; P2X4 - Hs00175706_m1; TLR4 - Hs00152937_m1; TRPV1 - 
Hs00218912_m1; TRPV4 - Hs01099348_m1; and TF2B - Hs00155321_m1.  TF2B 
(general transcription factor IIB) was used as the reference gene.  All primer probes, with 
the exception of the adrenergic genes and HTR1D (these genes do not have introns), 
recognize sequences that cross splice sites and therefore make detection of genomic DNA 
unlikely.  In all cases, we quenched the genomic DNA and ran no-template control wells 
to ensure that genomic DNA did not contaminate the final results.  All of the primer 
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probes were designed and tested to be used together and have similar efficiencies to help 
eliminate inaccuracy.  Evaluation of controls in this, and previous studies, indicated that 
TF2B had less intrinsic variation than other controls, had a count range that was similar 
to the genes of interest, and did not increase or decrease because of the exercise protocol 
(25, 27).  Real-time results were analyzed using SDS 2.1 (Applied Biosystems, Inc.) and 
were inspected to determine artifacts (loading errors, robot errors, threshold errors, etc.).  
Count numbers were exported to an Excel spreadsheet and analyzed according to the 
ddCT method described in the ABI User Bulletin #2 (Applied Biosystems, Inc.).  
Baseline levels for each gene were computed relative to TF2B, and these values were 
used as the comparator for all measures taken after the baseline period. 
 
Data Analyses   
Ratings of physical fatigue, mental fatigue, and pain were analyzed using 2 (trial) 
x 5 (time) RM ANOVAs.  Within-group time effects were examined with RM ANOVA 
with simple contrasts to determine which time points differed significantly from baseline.  
Between-trial differences in postexercise lactates, peak force, maximal rate of force 
development (MRFD), maximal rate of relaxation (MRR), contraction time (CT), 
reaction time (RT0.5), percent voluntary muscle activation (%VMA), potentiated twitch 
(Qtw.pot), and maximal voluntary contraction (MVC) were examined with RM ANOVA.  
For each subject, postexercise values for gene expression measures were 
normalized to baseline values (1.00=baseline).  Metabolite-detecting (ASIC1, ASIC3, 
P2X4, TRPV1, and TRPV4), immunologic (IL-6, IL-10, and TLR4), adrenergic 
(ADα2A, ADα2C, ADβ1, and ADβ2), and indolamine (HTR1D and DRD4) mRNAs 
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were examined using 2 x 5 RM ANOVAs with planned contrasts for evaluate time and 
trial effects.  All data were presented as means and standard deviations, with significance 
set at α˂0.05. 
 
 Results 
Exercise Performance and Subjective Responses 
By design, GXT was significantly shorter than TT (10.9 vs 74.3 min, p<0.001), 
but was more intense, as evidenced by significantly higher postexercise lactates 
(p<0.001), peak RPEs (p<0.05), and peak heart rates (p<0.01; see Table 2.1).  Significant 
time (F(4,48) > 4.8, p<0.003), exercise (GXT vs TT, F(1,12) > 8.3, p<0.014), and exercise 
by time (F(4,48) > 6.9, p<0.002) effects were found for ratings of postexercise physical 
fatigue and pain. Following TT, significant increases in physical fatigue were seen at 0.5, 
8, and 24 hours postexercise (p<0.005), and increases in pain were evident at 0.5 and 
hours postexercise (p<0.008, Figure 2.1). For mental fatigue after TT, a borderline 
significant time effect was noted (p=0.092), with trends for increases seen at 8 and 24 
hours postexercise.  After GXT, there were no significant increases in mental fatigue, 
physical fatigue, or pain following exercise (Figure 2.1).  
 
Neuromuscular Responses 
Peak force during the 5-second contraction was significantly lower than baseline 
values after both GXT and TT (p < 0.05), though there was not a significant difference 
between trials (p = 0.85).  Following both trials, Qtw.pot was significantly attenuated from 
pre-exercise values (p < 0.001) and to a greater extent following TT as compared to GXT 
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(p < 0.05, Table 2.2).  Additionally, MRFD and MRR decreased significantly from 
baseline after both trials, though there were no significant differences between trials. 
Contraction time (CT) decreased significantly after GXT but not after TT.  Percent 
muscle activation was significantly lower than baseline following both GXT (85.5%; p < 
0.001) and TT (91.4%; p < 0.01), but the degree of change was not different between the 
trials (p = 0.18). 
 
Gene Expression Measures 
Metabolite-detecting receptors.  Significant exercise (GXT vs TT, F(1,17) > 6.1, 
p<0.02), time (F(4,68) > 14.8, p<0.001), and exercise by time (F(4,68) > 4.4, p<0.003) 
effects were noted for ASIC3 and P2X4 (Figure 2.2). Across both treatments, ASIC3 and 
P2X4 decreased significantly at 0.5 hours postexercise, with significantly larger 
decreases seen after TT (p<0.001). In addition, ASIC3 and P2X4 mRNA levels remained 
significantly lower than baseline values at 8 hours post-TT (p<0.012). For TRPV1, 
significant time (F(4,68) = 19.1, p<0.001) and exercise by time (F(4,68) = 5.5, p=0.003) 
effects were observed, with significant decreases occurring at 0.5 and 8 hours after both 
GXT and TT; however, at 24 and 48 hours postexercise, TRPV1 levels returned to 
baseline after TT but remained significantly decreased at these time points after GXT. 
Postexercise ASIC1 and TRPV4 mRNA levels decreased significantly (F(4,68) >4.2, 
p<0.012) at 0.5 hours and at both 0.5 and 8 hours postexercise for ASIC1 and TRPV4, 




Adrenergic and indolamine receptors.   In contrast to the metabolite-detecting 
receptors, the adrenergic receptors, except for β2, increased their expression following 
exercise.  RM ANOVAs yielded significant time (F(4,68) > 4.3, p<0.004) and exercise by 
time (F(4,68)> 3.3, p<0.016) effects for α2C, β1, and β2.  Across both exercise trials, α2C 
mRNA increased significantly at 0.5 and 8 hours postexercise (p=0.042); however, 
examination of the exercise by time interaction indicated that only the increases 
following TT were statistically significant (p<0.006, Figure 2.3). Similarly, β1 mRNA 
increased significantly at 8 hours postexercise following both GXT and TT (p<0.004), 
but significant increases in β1 mRNA were also seen at 0.5 hours postexercise after TT 
(p=0.011). In addition to significant time and exercise by time effects, a significant 
exercise effect was also evident for β2 (F(1,17) = 7.8, p=0.013). β2 mRNA decreased 
significantly at 0.5 hours postexercise after TT, returning to baseline by 8 hours 
postexercise. After GXT, β2 mRNA was not significantly different from baseline at any 
postexercise time point. A significant time effect (F(4,68) = 4.7, p=0.004) was noted for 
α2A, with significantly higher levels observed at 0.5 and 8 hours postexercise across both 
exercise trials.  
Significant effects of exercise (F(1,17) = 5.3, p=0.034), time (F(4,68) = 4.3, 
p=0.004), and exercise by time (F(4,68) = 4.1, p=0.005) were also found for the serotonin 
receptor HTR1D.  At 0.5 and 8 hours after TT, HTR1D expression increased significantly 
above baseline (p<0.003) and then decreased toward baseline at 24 and 48 hours 
postexercise (Figure 2.4). In contrast, HTR1D expression increased from 0.5 to 24 hours 
postexercise after GXT, with significant increases in expression occurring at 8 hours 
postexercise (p=0.001). There was not a significant exercise effect for DRD4, although 
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time (F(4,68) = 28.4, p<0.001) and exercise by time (F(4,68) = 4.8, p=0.006) effects were 
significant. After TT, DRD4 mRNA was significantly lower than baseline levels at 0.5 
and 8 hours postexercise (p<0.042), while after GXT, DRD4 expression tended toward an 
increase at 0.5 hours postexercise (p=0.075) and decreased at 8 hours postexercise 
(p<0.001). 
Immune markers.  A significant exercise effect (F(1,17) = 5.6, p=0.031) was 
observed for IL-6 mRNA, which increased at all postexercise time points after GXT but 
not after TT (Figure 2.5). For TLR4, significant exercise by time (F(4,68) = 9.1, p<0.001) 
and time (F(4,68) = 10.9, p<0.001) effects were evident.  TLR4 increased earlier after TT, 
with significant increases occurring at 0.5 and 8 hours postexercise (p<0.001) and 
returning to baseline levels at 24 and 48 hours postexercise. After GXT, TLR4 mRNA 
increased significantly at 8 hours postexercise (p<0.001) and decreased more gradually 
toward baseline at 24 and 48 hours postexercise. A significant time effect was observed 
for IL-10 (F(4,48) = 21.4, p<0.001), with postexercise increases seen at 0.5, 8, and 24 
hours across both exercise treatments (p<0.025). 
 
 Discussion 
Main Findings  
The primary purpose of this study was to examine the perceptual fatigue and pain 
responses as well as the gene expression markers associated with fatigue following two 
different exercise trials; a graded exercise test and a 40k time trial.  By design, GXT was 
shorter, but more intense than TT as evidenced by higher postexercise lactate levels, peak 
heart rates, and peak RPE ratings.  However, the perceptual ratings of both physical 
34 
 
fatigue and pain were significantly increased for 24 hours following TT while unchanged 
following GXT.  This suggests that the longer duration, less intense TT causes long-term 
fatigue while GXT is not sufficient to produce lasting fatigue.  The higher lactate values 
following GXT suggest that the muscle was more acidic and had higher extracellular 
ATP concentrations as compared to TT (7, 21), though the exposure to heightened levels 
of these metabolites was more than 6 times longer during TT.  The increased levels of 
metabolites at the end of GXT should cause a greater activation of the Group III/IV 
afferent nerve fibers and may contribute to the cessation of exercise seen at the end of the 
GXT(26); however, the longer exposure of the nerves to metabolites during TT may 
provide the impetus for the more pronounced sensation of fatigue and the larger changes 
seen in postexercise mRNA gene expression. 
Mental fatigue, physical fatigue, and pain in healthy, trained individuals did not 
increase to the same absolute levels, nor did it last as long as our previous work in CFS 
patients, though our exercise trials were more intense (25, 27).  However, the relative 
increases in physical fatigue and pain from baseline to peak values following TT in 
healthy individuals roughly matched the relative increases from baseline in CFS patients 
following a 25-minute exercise trial (25, 27).  In CFS, perceptual responses tended to 
peak 8-24 hours after exercise and remain elevated for at least 48 hours (25, 27), while in 
healthy individuals, perceptual responses peaked at 0.5-8 hours before returning to 
baseline levels.  These increases in perceptual responses mirrored the largest gene 
expression changes in both healthy and CFS individuals as described below. 
Using more objective assessments of the contributions to muscular force, the level 
of peripheral fatigue as assessed by magnetic stimulation was significantly higher 
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following TT.  The level of peripheral fatigue following TT were similar to those found 
during a 5k time trial (3), suggesting that the participants in this trial reached a similar 
individual critical threshold of peripheral fatigue, even though the trial was 
approximately 10 times longer.  Despite lower lactate levels, TT demonstrated a larger 
change in Qtw.pot and subsequent peripheral fatigue than GXT.  While lactate contributes 
to afferent signaling(26), in a brief exercise test such as a graded exercise test, a long-
lasting sensation of fatigue (distinct from muscle fatigue as defined by a decrease in 
muscle performance) is unlikely to be explained solely by the metabolic contribution to 
central command via afferent signaling (1, 13).  This suggests that there may be 
additional central mechanisms for the cessation of exercise, perhaps supporting the idea 
of a central governor (38, 39).   
 
Gene Expression Changes Following GXT and TT Trials 
 We expected that a 40k time trial would produce greater sensory fatigue 
perception following exercise, eliciting greater changes in gene expression, though we 
were unsure that the direction of change would mirror that of the changes that were 
previously found to occur with CFS. 
 
Metabolite-detecting Receptors 
 The current study demonstrated marked decreases in mRNA for 8 hours 
postexercise before returning to baseline for both trials, though there were larger 
decreases in ASIC3, P2X4, and TRPV1 following TT.  In contrast to the transient 
decreases in mRNA for the metabolite-detecting receptors found in the current study, our 
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previous work demonstrated marked increases in CFS patients (25, 27, 54).  The 
decreases in metabolite-detecting receptors in healthy individuals may be indicative of a 
healthy adaptive down-regulation following receptor activation in an attempt to reduce 
receptor sensitization and the sensation of fatigue following exercise (54).  Though peak 
metabolite levels may be lower during TT than GXT, the activation of the receptors may 
be prolonged due to the extended exercise duration, leading to increased perceptual 
fatigue and subsequently larger decreases in gene expression.  These larger decreases in 
mRNA following TT may lead to a greater exercise adaptation through an attempt to 
‘reset’ the fatigue signal to pre-exercise levels.  Finally, our data suggest that the 
magnitude of change in the mRNA for metabolite-detecting receptors may be work 
related, with larger magnitudes, or durations, of work leading to larger decrements in 
gene expression.   
The decreases in metabolite-detecting mRNA following exercise are consistent 
with a recent viewpoint paper by Smith (48) that suggested the “no pain, no gain” 
colloquial phrase may in fact rely on the ability to push through fatigue in order to 
maximize the benefits of exercise training.  In healthy individuals, a single bout of 
exercise reduces the amount of mRNA for fatigue and pain sensing metabolite detectors, 
with a more strenuous and painful exercise causing larger changes.  With consistent 
training, there may be a further down-regulation in the number and perhaps sensitivity of 
these metabolite detecting receptors, reducing the perception of fatigue and pain felt 
during subsequent similar exercise bouts, leading to performance increases independent 





 Following exercise, expression of the adrenergic receptors, with the exception of 
β2 following TT, increased following exercise.  The general increases during this study 
were similar to the changes that were found with CFS (25, 27, 54), though our increases 
were attenuated and returned to baseline levels by 24 hours after exercise.  However, the 
CFS group had increases in adrenergic β2 (25, 27, 54), whereas we found an initial 
decrease or no change following exercise in healthy individuals.  Further, it appears that 
the intensity and duration of the GXT was not great enough to cause significant changes 
in gene expression. 
One of the primary roles of β-adrenergic receptors is the control of blood flow, 
both by enhancing contractility and heart rate via the β1 receptor and by causing dilation 
of arteries supplying the working muscle by activation of the β2-receptor.  β2 receptors 
are also important in exercise training, as activation enhances anaerobic metabolism and 
muscle oxidation (47).  Within the arteries, alpha-2 receptor activation is known to cause 
vasoconstriction and reduction in blood flow (16).  During a healthy exercise response, it 
may be expected that the adrenergic receptors would change to increase blood flow 
during both exercise and rest to reduce metabolite accumulation and afferent signal.  
However, following the time trial, the increase in α-adrenergic mRNA and decrease in β2 
receptors may reflect a decrease in blood flow for up to 0.5-8 hours following exercise, 
leading to increased metabolite levels during both rest and subsequent exercise.  The 
adrenergic receptors may also aid in the sympathetic nervous system response on the 





 We determined that TLR4 mRNA was upregulated after both GXT and TT.  
TLR4 was upregulated immediately after TT, but not until 8 hours after GXT.  We also 
determined that IL-6 mRNA was upregulated after GXT as compared to no change after 
TT.  TLR4 is an indicator of inflammation; whereas IL-6 is an anti-inflammatory 
myokine (44) that may increase cortisol release following exercise (20), may increase the 
sensitivity of the vasculature to the sympathetic signal (23), or cause vasodilation of the 
arterioles (34).  When compared to a study by Nieman et al., in which cyclists completed 
a 2-hour cycling bout at 60-65% of Wattsmax in which no change in IL-6 mRNA was 
found, we found increased gene expression following GXT but not TT (36).  The primary 
difference between the two trials was the GXT duration was less than 11 minutes and the 
intensity was much greater than TT.  The moderate decrease in IL-6 gene expression 
beginning at 8 hours and lasting until 24 hours, as well as the increases in TLR4, 
following TT suggests that the cyclists may have been undergoing a temporary 
depression in immune function or sympathetic tone, allowing an increased blood flow 
following exercise (23).   
 
Indolamine Receptors 
Following TT, there were larger increases in the serotonin receptor and larger 
decreases in the dopamine receptor than after GXT.  Serotonin and dopamine have been 
implicated in fatigue, though HTR1D and DRD4 gene expression have not been 
examined in CFS.  Previous studies have described how serotonin and dopamine may 
cause central fatigue (5, 29-31, 35), but have ignored the possible effects in the periphery 
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and the sensory afferent nerves.  We found that the serotonin receptor had 8-30 fold 
increases following exercise and remained elevated for at least 8 hours postexercise, with 
larger increases following TT.  During exercise, elevated quantities of serotonin lead to 
decreased motivation (11) and serotonin quantities tend to peak at the point of fatigue.  
Activation of the 5-HT receptor increases afferent signal in rats (51) and causes a short, 
but modest, increase in pain when directly injected into human muscle (32).  Unlike 
serotonin, the dopamine receptor had decreases of almost 50% at 8 hours after exercise.  
Activation of the dopamine receptor has been shown to inhibit depolarization of afferent 
nerves (9, 46).  Thus, a decrease in the number of dopamine receptors could lead to 
increased activation of the afferent nerve and, even at rest, an increase in fatigue 
sensation.  The combination of an increase in serotonin receptor and the concurrent 
decrease in dopamine receptor mRNA may lead to increased sensations of fatigue and 
reduced motivation following exercise (31).   
 
Methodological Qualifications 
 A limitation of this study is that gene expression was assessed in leukocytes and 
may not represent changes in brain, muscle, or other tissues.  In addition, it is unclear 
how changes in gene expression would affect protein synthesis or quantities with any of 
the genes under study.  Future studies should determine the relationships between 






The longer, less intense TT produced longer-lasting perceived fatigue and pain, 
more peripheral fatigue, and greater mRNA gene expression changes than the shorter, but 
more intense GXT.  Also, the normal exercise response is different in healthy individuals 
than individuals with CFS, even when the increase in perceived physical fatigue during 
exercise is matched between groups.  CFS patients have large increases in metabolite-
detecting genes following exercise while a healthy response consists of a decrease in 
these same genes.  CFS patients also demonstrate an increase in adrenergic β2 mRNA 
while a healthy response consists of a smaller increase in α2a, α2c, and β1 and no change 
or a decrease in β2 mRNA.  These findings aid in describing the normal gene expression 
response to exercise as compared to the abnormal response seen in patients with CFS.  
These gene alterations suggest that increases in adrenergic and serotonin gene expression 
and the concurrent decrease in dopamine gene expression may lead to an increased 
resting afferent signal, leading to increased fatigue and decreased motivation.  The 
decrease in metabolite-detecting receptor gene expression may be an attempt to return the 
fatigue signal to homeostasis.  The combination of changes in all of the receptors 
following exercise may possibly contribute to the prolonged sensation of fatigue 





1. Amann M, and Dempsey JA. Locomotor muscle fatigue modifies central motor 
drive in healthy humans and imposes a limitation to exercise performance. J 
Physiol 586: 161-173, 2008. 
2. Amann M, Eldridge MW, Lovering AT, Stickland MK, Pegelow DF, and 
Dempsey JA. Arterial oxygenation influences central motor output and exercise 
performance via effects on peripheral locomotor muscle fatigue in humans. J 
Physiol 575: 937-952, 2006. 
3. Amann M, Proctor LT, Sebranek JJ, Pegelow DF, and Dempsey JA. Opioid-
mediated muscle afferents inhibit central motor drive and limit peripheral muscle 
fatigue development in humans. J Physiol 587: 271-283, 2009. 
4. Amann M, Romer LM, Subudhi AW, Pegelow DF, and Dempsey JA. Severity 
of arterial hypoxaemia affects the relative contributions of peripheral muscle 
fatigue to exercise performance in healthy humans. J Physiol 581: 389-403, 2007. 
5. Bailey SP, Davis JM, and Ahlborn EN. Effect of increased brain serotonergic 
activity on endurance performance in the rat. Acta Physiol Scand 145: 75-76, 
1992. 
6. Bailey SP, Davis JM, and Ahlborn EN. Neuroendocrine and substrate responses 
to altered brain 5-HT activity during prolonged exercise to fatigue. J Appl Physiol 
74: 3006-3012, 1993. 
7. Bangsbo J, Johansen L, Graham T, and Saltin B. Lactate and H+ effluxes from 
human skeletal muscles during intense, dynamic exercise. J Physiol 462: 115-133, 
1993. 
8. Bigland-Ritchie B, and Woods JJ. Changes in muscle contractile properties and 
neural control during human muscular fatigue. Muscle Nerve 7: 691-699, 1984. 
9. Birrell MA, Crispino N, Hele DJ, Patel HJ, Yacoub MH, Barnes PJ, and 
Belvisi MG. Effect of dopamine receptor agonists on sensory nerve activity: 
possible therapeutic targets for the treatment of asthma and COPD. Br J 
Pharmacol 136: 620-628, 2002. 
10. Bliss EL, and Ailion J. Relationship of stress and activity to brain dopamine and 
homovanillic acid. Life Sci I 10: 1161-1169, 1971. 
11. Blomstrand E, Celsing F, and Newsholme EA. Changes in plasma 
concentrations of aromatic and branched-chain amino acids during sustained 
exercise in man and their possible role in fatigue. Acta Physiol Scand 133: 115-
121, 1988. 
12. Cafarelli E. Peripheral contributions to the perception of effort. Med Sci Sports 
Exerc 14: 382-389, 1982. 
42 
 
13. Calbet JA. The rate of fatigue accumulation as a sensed variable. J Physiol 575: 
688-689, 2006. 
14. Chaudhuri A, and Behan PO. Fatigue and basal ganglia. J Neurol Sci 179: 34-
42, 2000. 
15. Chaudhuri A, and Behan PO. Fatigue in neurological disorders. The Lancet 
363: 978-988, 2004. 
16. Eklund B, and Kaijser L. Effect of regional alpha-and beta-adrenergic blockade 
on blood flow in the resting forearm during contralateral isometric handgrip. J 
Physiol 262: 39-50, 1976. 
17. Elenkov IJ, Wilder RL, Chrousos GP, and Vizi ES. The sympathetic nerve—
an integrative interface between two supersystems: the brain and the immune 
system. Pharmacological reviews 52: 595-638, 2000. 
18. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, and Komaroff A. 
The chronic fatigue syndrome: a comprehensive approach to its definition and 
study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 
121: 953-959, 1994. 
19. Gandevia SC. Spinal and supraspinal factors in human muscle fatigue. Physiol 
Rev 81: 1725-1789, 2001. 
20. Gleeson M. Immune function in sport and exercise. J Appl Physiol 103: 693-699, 
2007. 
21. Hellsten Y, Sjodin B, Richter EA, and Bangsbo J. Urate uptake and lowered 
ATP levels in human muscle after high-intensity intermittent exercise. Am J 
Physiol 274: E600-606, 1998. 
22. Johnson SK, DeLuca J, and Natelson BH. Chronic fatigue syndrome: reviewing 
the research findings. Ann Behav Med 21: 258-271, 1999. 
23. Kelly JJ, Mangos G, Williamson PM, and Whitworth JA. Cortisol and 
hypertension. Clin Exp Pharmacol Physiol Suppl 25: S51-56, 1998. 
24. Kos D, Kerckhofs E, Nagels G, D'Hooghe M B, and Ilsbroukx S. Origin of 
fatigue in multiple sclerosis: review of the literature. Neurorehabil Neural Repair 
22: 91-100, 2008. 
25. Light AR, Bateman L, Jo D, Hughen RW, Vanhaitsma TA, White AT, and 
Light KC. Gene expression alterations at baseline and following moderate 
exercise in patients with Chronic Fatigue Syndrome and Fibromyalgia Syndrome. 
J Intern Med 2011. 
26. Light AR, Hughen RW, Zhang J, Rainier J, Liu Z, and Lee J. Dorsal root 
ganglion neurons innervating skeletal muscle respond to physiological 
43 
 
combinations of protons, ATP, and lactate mediated by ASIC, P2X, and TRPV1. 
J Neurophysiol 100: 1184-1201, 2008. 
27. Light AR, White AT, Hughen RW, and Light KC. Moderate exercise increases 
expression for sensory, adrenergic, and immune genes in chronic fatigue 
syndrome patients but not in normal subjects. J Pain 10: 1099-1112, 2009. 
28. Light KC, Bragdon EE, Grewen KM, Brownley KA, Girdler SS, and 
Maixner W. Adrenergic dysregulation and pain with and without acute beta-
blockade in women with fibromyalgia and temporomandibular disorder. J Pain 
10: 542-552, 2009. 
29. Meeusen R, and Watson P. Amino acids and the brain: do they play a role in 
"central fatigue"? Int J Sport Nutr Exerc Metab 17 Suppl: S37-46, 2007. 
30. Meeusen R, Watson P, Hasegawa H, Roelands B, and Piacentini MF. Brain 
neurotransmitters in fatigue and overtraining. Appl Physiol Nutr Metab 32: 857-
864, 2007. 
31. Meeusen R, Watson P, Hasegawa H, Roelands B, and Piacentini MF. Central 
fatigue: the serotonin hypothesis and beyond. Sports Med 36: 881-909, 2006. 
32. Mense S. Algesic agents exciting muscle nociceptors. Experimental brain 
research 196: 89-100, 2009. 
33. Merton PA. Voluntary strength and fatigue. J Physiol 123: 553-564, 1954. 
34. Minghini A, Britt LD, and Hill MA. Interleukin-1 and interleukin-6 mediated 
skeletal muscle arteriolar vasodilation: in vitro versus in vivo studies. Shock 9: 
210-215, 1998. 
35. Newsholme EA, and Blomstrand E. Tryptophan, 5-hydroxytryptamine and a 
possible explanation for central fatigue. Adv Exp Med Biol 384: 315-320, 1995. 
36. Nieman DC, Henson DA, Davis JM, Dumke CL, Utter AC, Murphy EA, 
Pearce S, Gojanovich G, McAnulty SR, and McAnulty LS. Blood leukocyte 
mRNA expression for IL-10, IL-1Ra, and IL-8, but not IL-6, increases after 
exercise. J Interferon Cytokine Res 26: 668-674, 2006. 
37. Nijs J, Van de Putte K, Louckx F, Truijen S, and De Meirleir K. Exercise 
performance and chronic pain in chronic fatigue syndrome: the role of pain 
catastrophizing. Pain Med 9: 1164-1172, 2008. 
38. Noakes TD, Peltonen JE, and Rusko HK. Evidence that a central governor 
regulates exercise performance during acute hypoxia and hyperoxia. J Exp Biol 
204: 3225-3234, 2001. 
39. Noakes TD, St Clair Gibson A, and Lambert EV. From catastrophe to 
complexity: a novel model of integrative central neural regulation of effort and 
fatigue during exercise in humans. Br J Sports Med 38: 511-514, 2004. 
44 
 
40. Nybo L. Hyperthermia and fatigue. J Appl Physiol 104: 871-878, 2008. 
41. Nybo L, and Nielsen B. Perceived exertion is associated with an altered brain 
activity during exercise with progressive hyperthermia. J Appl Physiol 91: 2017-
2023, 2001. 
42. Okamura K, Matsubara F, Yoshioka Y, Kikuchi N, Kikuchi Y, and Kohri H. 
Exercise-induced changes in branched chain amino acid/aromatic amino acid ratio 
in the rat brain and plasma. Jpn J Pharmacol 45: 243-248, 1987. 
43. Patrick Neary J, Roberts AD, Leavins N, Harrison MF, Croll JC, and 
Sexsmith JR. Prefrontal cortex oxygenation during incremental exercise in 
chronic fatigue syndrome. Clin Physiol Funct Imaging 28: 364-372, 2008. 
44. Pedersen BK, and Febbraio MA. Muscle as an endocrine organ: focus on 
muscle-derived interleukin-6. Physiol Rev 88: 1379-1406, 2008. 
45. Pollak KA, Swenson JD, Vanhaitsma TA, Hughen RW, Jo D, Light KC, 
Schweinhardt P, Amann M, and Light AR. Exogenously applied muscle 
metabolites synergistically evoke sensations of muscle fatigue and pain in human 
subjects. Exp Physiol 99: 368-380, 2014. 
46. Rosenkranz JA, and Grace AA. Modulation of basolateral amygdala neuronal 
firing and afferent drive by dopamine receptor activation in vivo. The Journal of 
Neuroscience 19: 11027-11039, 1999. 
47. Scheidegger K, Robbins DC, and Danforth E, Jr. Effects of chronic beta 
receptor stimulation on glucose metabolism. Diabetes 33: 1144-1149, 1984. 
48. Smith SA. No pain, no gain: somatosensation from skeletal muscle. Exp Physiol 
99: 340-341, 2014. 
49. St Clair Gibson A, Baden DA, Lambert MI, Lambert EV, Harley YX, 
Hampson D, Russell VA, and Noakes TD. The conscious perception of the 
sensation of fatigue. Sports Med 33: 167-176, 2003. 
50. St Clair Gibson A, and Noakes TD. Evidence for complex system integration 
and dynamic neural regulation of skeletal muscle recruitment during exercise in 
humans. Br J Sports Med 38: 797-806, 2004. 
51. Sung D, Dong X, Ernberg M, Kumar U, and Cairns BE. Serotonin (5-HT) 
excites rat masticatory muscle afferent fibers through activation of peripheral 5-
HT< sub> 3</sub> receptors. Pain 134: 41-50, 2008. 
52. Utter AC, Kang J, Nieman DC, Williams F, Robertson RJ, Henson DA, Davis 
JM, and Butterworth DE. Effect of carbohydrate ingestion and hormonal 
responses on ratings of perceived exertion during prolonged cycling and running. 
Eur J Appl Physiol Occup Physiol 80: 92-99, 1999. 
45 
 
53. Weinstein AA, Drinkard BM, Diao G, Furst G, Dale JK, Straus SE, and 
Gerber LH. Exploratory analysis of the relationships between aerobic capacity 
and self-reported fatigue in patients with rheumatoid arthritis, polymyositis, and 
chronic fatigue syndrome. Pm R 1: 620-628, 2009. 
54. White AT, Light AR, Hughen RW, Vanhaitsma TA, and Light KC. 
Differences in metabolite-detecting, adrenergic, and immune gene expression 
after moderate exercise in patients with chronic fatigue syndrome, patients with 
multiple sclerosis, and healthy controls. Psychosom Med 74: 46-54, 2012. 
55. Wilson WM, and Maughan RJ. Evidence for a possible role of 5-
hydroxytryptamine in the genesis of fatigue in man: administration of paroxetine, 
a 5-HT re-uptake inhibitor, reduces the capacity to perform prolonged exercise. 






Table 2.1. Subject and exercise characteristics. 
Age 36.1 ± 9.7  
Weight (kg) 68.1 ± 9.2  
Training History 
(miles/week) 
77.6 ± 37.6  
Riding experience (years) 8.2 ± 9.3  
VO2peak (mL/kg/min) 54.8 ± 5.9  
 GXT TT p-value 
Exercise Time (min) 10.9 ± 1.2 74.3 ± 6.0 * <0.001 
Total Work (kJ) 2.18 ± 0.3 13.93 ± 2.9 * <0.001 
1-min Post-ex Lactate 
(mmol/L) 
12.4 ± 0.8 8.9 ± 0.9 * <0.001 
5-min Post-ex Lactate 
(mmol/L) 
10.0 ± 1.2 6.7 ± 0.8 * 0.008 
Peak HR (bpm) 183.9 ± 9.7 176.2 ± 13.5 * 0.003 
Peak RPE (6-20) 18.6 ± 1.0 17.7 ± 1.7 * <0.05 
Average HR (bpm) - 164 ± 15.0 N/A 
Average RPE (6-20) - 15.5 ± 1.46 N/A 
Values are mean ± SD; n = 20.  HR = heart rate, RPE = ratings of perceived exertion.  * 





Table 2.2. Effects of GXT and TT on quadriceps muscle function 
 Percentage change from pre- to 2 min 
postexercise 
 GXT 40k time trial p-value 
Qtw.pot (N) -26.5 ± 12.4 -32.7 ± 11.1 .04 
MRFD (N·s-1) -28.9 ± 15.1 -34.6 ± 16.9 .29 
MRR (N·s-1) -31.9 ± 19.2 -35.6 ± 15.9 .09 
CT (s) -3.8 ± 5.5 2.9 ± 8.3 † .07 
RT0.5 (s) 3.1 ± 19.1 † -3.0 ± 13.0 † .44 
MVC peak force (N) -10.1 ± 7.8 -9.5 ± 8.6 .85 
Percentage voluntary muscle 
activation 
-14.5 ± 11.0 -8.6 ± 8.5 .18 
Peripheral fatigue was assessed via supramaximal magnetic stimulation of the femoral 
nerve before and 2 min after exercise.  Changes in fatigue variables are expressed as a 
percentage change from pre-exercise baseline.  Values are expressed as means ± S.D.  
Abbreviations: Qtw.pot, potentiated single twitch; MRFD, maximal rate of force 
development; MRR, maximal rate of relaxation; CT, contraction time, RT0.5, one-half 
relaxation time; and MVC, maximal voluntary contraction.  Percentage muscle activation 
is based on superimposed twitch technique.  Most of the variables changed significantly 
when comparing baseline and 2 min after exercise (p < 0.05). † Not significantly different 
from pre-exercise baseline.  Pre-exercise, resting mean values before GXT for potentiated 
single twitch, MRFD, MRR, CT, and RT0.5 were 165.3 ± 32.0 N, 3006.5 ± 511.4 N s-1, 
2221.5 ± 958.1 N s-1, .175 ± .0172 s, and .045 ± .006 s, respectively.  Pre-exercise, 
resting mean values before TT were 164.1 ± 39.7 N, 2948.9 ± 849.3 N s-1, 2272.5 ± 






Figure 2.1.  Ratings of mental fatigue, physical fatigue, and pain at the times indicated.  
Ratings were based on a 0 to 100 scale.  Baseline indicates before exercise; 0.5 = one half 
hour after exercise; 8 = 8 hours after exercise; 24 = 24 hours after exercise; 48 = 48 hours 
after exercise. 
a refers to a significant overall exercise effect (p<0.05) 
b refers to a significant overall exercise by time interaction (p<0.05)   






















































Figure 2.2.  Amount of mRNA for ASIC1, ASIC3, P2X4, TRPV1, and TRPV4 expressed 
as fold changes relative to baseline levels at each of the times indicated before (baseline) 
and after the indicated exercise (GXT = graded exercise test; TT = 40k time trial). 
a refers to a significant overall exercise effect (p<0.05) 
b refers to a significant overall exercise by time interaction (p<0.05)   



















































Figure 2.3.  Amount of mRNA α2a, α2c, β1, and β2 adrenergic receptors expressed as 
fold changes relative to baseline levels at each of the times indicated before (baseline) 
and after the indicated exercise (GXT = graded exercise test; TT = 40k time trial). 
a refers to a significant overall exercise effect (p<0.05) 
b refers to a significant overall exercise by time interaction (p<0.05)   














































Figure 2.4.  Amount of mRNA for HTR1D and DRD4 indolamine receptors expressed as 
fold changes relative to baseline levels at each of the times indicated before (baseline) 
and after the indicated exercise (GXT = graded exercise test; TT = 40k time trial). 
a refers to a significant overall exercise effect (p<0.05) 
b refers to a significant overall exercise by time interaction (p<0.05)   





































Figure 2.5.  Amount of mRNA for IL-6, IL-10, and TLR4 immune function genes 
expressed as fold changes relative to baseline levels at each of the times indicated before 
(baseline) and after the indicated exercise (GXT = graded exercise test; TT = 40k time 
trial). 
a refers to a significant overall exercise effect (p<0.05) 
b refers to a significant overall exercise by time interaction (p<0.05)   
















































 EFFECT OF HEAT STRESS ON FATIGUE SENSATION  
 AND GENE EXPRESSION IN TRAINED CYCLISTS  








Heat stress has a negative impact on endurance exercise performance, resulting in 
decreased work output and increased effort and fatigue perception. We examined, in 
healthy trained cyclists (n= 20), the effect heat stress (35°C; HT) compared to ambient 
conditions (21°C; AT) on 40k time trial performance, immediate and longer term 
postexercise perceptions of fatigue and pain, and transcriptional alterations in the mRNA 
of exercise and immune function-related genes.  Blood lactates were measured 1 and 5 
minutes postexercise and blood draws were performed at baseline and at 0.5, 8, 24, and 
48 hours postexercise.  Leukocytes were separated for RNA extraction and qPCR 
analysis was performed for metabolite detecting, adrenergic, indolamine, and immune 
receptors.  Core temperature was significantly higher during HT (p˂0.05) while power 
and lactates were significantly higher during AT (p˂0.05).  Physical fatigue and pain 
sensations were increased for 8 hours following both AT and HT (p˂0.05).  Both trials 
resulted in significant postexercise decreases in metabolite detecting receptors ASIC1, 
ASIC3, P2X4, TRPV1, and TRPV4; increases in adrenergic receptors α2a, α2c, and β1; 
decreases in adrenergic β2, the immune receptor TLR4, and dopamine (DRD4); and 
increases in serotonin (HTR1D) and IL-10 (p<0.05).  Postexercise IL-6 differed between 
AT and HT, with significantly greater increases observed following HT (p<0.05). 
Although lactates were higher following AT, postexercise changes in mRNA were 
similar between the trials.  Thus, heat stress may ‘act’ like a metabolite, increasing 
inhibitory afferent signaling during exercise, causing decreased motor command that 





Heat stress has a negative impact on endurance exercise performance, resulting in 
decreased work output and increased effort and fatigue perception (12, 21, 23, 24, 31, 
54). Cardiovascular strain likely contributes to performance decrements during heat stress 
(13), but hyperthermic fatigue is multifactorial (12, 16, 21, 31). Increases in core 
temperature and heat storage rates during exercise alter central nervous system (CNS) 
function, resulting in reduced voluntary muscle activity and increased fatigue perception 
(19, 21, 35, 36, 57).  
Heat-related alterations in CNS function may be mediated by several 
mechanisms.  Inhibitory feedback from thermoreceptors in the hypothalamus may inhibit 
central motor drive (39, 40).  For example, when the head is cooled during exercise, 
decreasing the temperature of the brain and hypothalamus, time to fatigue is increased, 
suggesting that directly reducing inputs from brain heat sensors prevents decreases in 
CNS drive (4).   
Several neurotransmitters, particularly the indolamines dopamine (DA) and 
serotonin (5-HT), may play a role in the development of fatigue during prolonged 
exercise (39). Serotonergic activity influences arousal levels that may improve exercise 
performance. It has also been shown that endurance performance is impaired in rats that 
had received a 5-HT agonist (7). In addition, tissue levels of DA and 5-HT have been 
shown to increase during exercise, but DA levels decrease substantially at exhaustion (6). 
This suggests that the ratio of 5-HT/DA may be important in the development of central 
fatigue (6, 16, 50, 58, 60). Further evidence supports the idea that these neurotransmitters 
play an important role specifically during endurance exercise in the heat. Administration 
of bupropion, a DA/noradrenaline uptake inhibitor, resulted in improved time trial 
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performance in the heat (50). 
Another factor that may increase central fatigue during exercise is stimulation of 
the group III/IV afferents by a combination of metabolites, including protons, ATP, and 
lactate, which activate five molecular receptors, including ASIC3 (Acid-sensing Inward 
Current), P2X (purinergic) type 4 and 5, and TRPV (transient receptor potential 
vanilloid) type 1 and 4, signaling both fatigue and pain (26, 29, 47).  In addition to being 
sensitive to metabolites, TRPV receptors are highly responsive to heat, with a threshold 
as low as 25°C and increased responsiveness to temperatures as high as 50°C (10, 14).  It 
is possible that TRPV1 molecular receptors influence responses of metaboreceptive 
neurons innervating skeletal muscle as muscle temperature increases.  This is consistent 
with observed increases in sympathetic response with muscle heating (48).  The overall 
effect would be that heat-stress is perceived as a metabolite, and along with changing 
concentrations of protons, lactate, and ATP, amplifies the peripheral fatigue signal during 
exercise in the heat, potentially adding to the brain thermoreceptor signal to increase 
central fatigue. 
 The purpose of this investigation was to examine the effects of a 40K time trial in 
two different environments, a typical ambient environment (21 °C, ambient trial (AT)) 
and a warm (35°C, heat trial (HT)) environment, on immediate and longer term 
postexercise responses of fatigue and pain sensations (using visual analog scales- VAS) 
and transcriptional alterations in the mRNA of exercise and immune function-related 
genes in healthy, fit individuals.   
 We hypothesized that performance of a 40K time trial under heat-stressed 
conditions would produce higher levels of fatigue and pain sensations compared to 
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exercise during ambient conditions.  Further, we expected that fatigue and pain 
perception would remain elevated longer after HT compared to AT.  In addition, we 
hypothesized that mRNA for genes implicated in transducing the additional fatigue and 
pain signaling produced by heat stress (ASIC3, P2X4, TRPV1, and TRPV4) would be 
increased in blood leukocytes to a greater extent following HT than AT.  Along with 
these sensory receptors, we hypothesized that proinflammatory cytokines (putative 
mediators of the sickness response) and their receptor mRNAs for IL6 and TLR4 would 
be elevated following time trials in the heat because the “sickness response” can be 
induced by working in the heat.  Finally, we hypothesized that adrenergic receptors (α2a, 
α2c, β1, and β2) and the serotonin receptor (HTR1D) that may mediate sympathetic 
responses to increased muscle and core temperatures, and/or may also play a role in 
signaling leukocytes to mount a protective response to heat stress, would also increase.  
We expected these increases would be seen immediately following exhausting exercise 




  All experimental procedures in this investigation were reviewed and approved by 
the University of Utah Institutional Review Board.  The protocols and procedures were 
explained, and all participants provided written informed consent prior to testing.  
Twenty healthy, moderately trained male (n=10) and female (n=10) cyclists between the 
ages of 18-55 were recruited for this investigation (mean ± SD; age 36.1 ± 9.7 years, 
body weight 68.1 ± 9.2 kg, height 172.9 ± 6.3 cm, peak oxygen consumption (VO2peak) 
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54.8 ± 5.9 mL/kg/min). Cyclists were excluded if any of the following applied: current 
acute musculoskeletal injury; medications known to interfere with the sympathetic 
nervous system; unwillingness to comply with training interruptions mandated by the 
protocol; any uncontrolled chronic health condition.  
 
Protocol Overview   
Participants performed three exercise tests, separated by at least 1 week: a graded 
exercise test to determine VO2peak and two 40K time trials, one in a typical ambient 
environment (21 °C, ambient trial (AT))  and one in a warm environment (35°C, heat trial 
(HT)) on a Velotron cycle ergometer (Racermate, Seattle WA).  All participants refrained 
from exercise for 24 hours prior to the exercise test.  The ergometer was adjusted to 
match each participant’s accustomed cycle position, and participants used their own cycle 
shoes and pedals.  Venous blood samples were obtained from the arm at baseline and at 
0.5, 8, 24, and 48 hours after the two 40K time trials.  To assess the severity of 
preexisting and exercise-related fatigue and pain symptoms at the time of each blood 
draw, participants provided numerical ratings of physical fatigue and overall body pain or 
soreness using a 0-100 scale, where 100 was defined as the greatest amount of fatigue or 
pain the participant could ever imagine experiencing.  Immediately after the baseline 
blood draw, participants began the exercise test as described below. 
 
Experimental Protocol  
 On the first experimental day, participants performed an incremental cycling test 
(VO2peak) beginning at 100W (50W for females) with resistance increasing 25W every 
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minute until volitional exhaustion.  Participants pedaled at their preferred pedaling rate, 
and the test was terminated when the cadence dropped more than 10 rpm for more than 5 
seconds despite strong verbal encouragement to increase the cadence.  Metabolic data 
were collected using open circuit calorimetry (Parvomedics, True Max 2400, Sandy, UT).  
Peak oxygen consumption (VO2peak) was recorded as the highest VO2 recorded in a 15-
second period. 
On the next two experimental days, in random order, participants performed a 
40K time trial at typical ambient temperature (AT; 21 °C, 20-30% humidity) or in a 
warm environmental chamber (HT; 35 °C, 25-35% humidity) in order to simulate an 
intense training ride.  Following a 10-15-minute self-selected warm-up, the trial began, 
with participants able to fully control the gearing of the Velotron.  Participants received 
feedback of speed, power, distance covered, and cadence and were strongly encouraged 
to cover the distance as fast as possible.  Core temperature (Tcore) was measured via a 
rectal thermistor (YSI Precisions 4400 Series; Yellow Springs Instruments, Yellow 
Springs, OH, USA) inserted to a depth of 15 cm from the external sphincter.  Heart rate, 
Tcore, time, and power were recorded every 2.5 km.  Thermal sensation (20), thermal 
comfort, rating of perceived exertion (RPE), and VAS ratings of physical fatigue and 
pain were recorded every 5 km.  Upon completion of the test, participants were 
encouraged to cool down for 5-10 minutes before cessation of exercise.   
Blood samples obtained at baseline and 0.5, 8, 24, and 48 hours after each time 
trial were collected in EDTA tubes.  Samples were quickly centrifuged (within 5 minutes 
of collection) at 4100rpm (2.6rcf, Eppendorf Centrifuge 5702R) for 12 minutes. 
Immediately after, the white cell layer was carefully collected in RLT + βME (Qiagen, 
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Valencia, CA, USA) and quickly frozen using a methanol-dry ice slurry and stored at -
80°C.  RNA was extracted using RNeasy kits (Qiagen), according to manufacturer’s 
directions, and treated with RNase-free DNase-I (Qiagen) to eliminate possible genomic 
contamination.  Immediately following extraction, RNA was converted to a cDNA 
library using the ABI High Capacity cDNA Archive kit (Applied Biosystems, Inc., Foster 
City, CA, USA).  The cDNA was stored at -20 °C until analysis. 
The cDNA libraries were analyzed using the ABI quantitative, real-time PCR 
system on the ABI Prism 7900 Sequence Detection System (Applied Biosystems, Inc.) 
using ABI Taqman Master Mix (Applied Biosystems, Inc.).  Master mix/primer probe 
solutions were separately loaded onto 96-well preplates, with robot loading mixing these 
solutions when placed into 384 plates.  Plates were centrifuged to remove air bubbles 
from the wells.  Each sample was run in duplicate with the standards run in 
quadruplicate.  No-template control samples were also run to eliminate potential 
contamination.  Each 384-well plate contained eight samples and all genes were analyzed 
on the same plate.  Primer probes (all from Taqman Gene Expression Assays; Applied 
Biosystems, Inc.) were as follows; 
Adrenergic A2A (α-2A) – HS00265081_s1; Adrenergic A2C (α-2C) - HS03044628_s1; 
Adrenergic B-1 - Hs02330048_s1; Adrenergic B-2 - Hs00240532_s1; ASIC1 - 
Hs00241630_m1; ASIC3 - Hs00245097_m1; DRD4 - Hs00609526_m1; HTR1D - 
Hs00704742_s1; IL10 - Hs00174086_m1; IL6 - Hs00174131_m1; P2X4 - 
Hs00175706_m1; TLR4 - Hs00152937_m1; TRPV1 - Hs00218912_m1; TRPV4 - 
Hs01099348_m1; and TF2B - Hs00155321_m1. TF2B was used as the reference gene.  
All primer probes, with the exception of the adrenergic genes, and HTR1D, (these genes 
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do not have introns), recognize sequences that cross splice sites and therefore make 
detection of genomic DNA unlikely. All of the primer probes were designed and tested to 
be used together and have similar efficiencies to allow cross comparisons of quantities.  
Evaluation of controls in this and previous studies indicated that TF2B had less intrinsic 
variation than other controls, had a count range that was similar to the genes of interest, 
and did not change in response to the exercise protocol (28, 30).  Real-time qPCR results 
were analyzed using SDS 2.1 (Applied Biosystems, Inc.) and were inspected to determine 
artifacts (loading errors, robot errors, threshold errors, etc.).  Count numbers were 
exported to an Excel spreadsheet and analyzed according to the ddCT method described 
in the ABI User Bulletin #2 (Applied Biosystems, Inc.).  Baseline levels for each gene 
were computed relative to TF2B, and these values were used as the comparator for all 
measures taken after the baseline period. 
 
Data Analysis   
To evaluate treatment (AT vs HT) and time effects, as well as time by treatment 
interactions during exercise, repeated measures (RM) ANOVAs were performed for 
physiological (Tcore, power, and heart rate) and perceptual (RPE and ratings of physical 
fatigue and pain) responses. If time effects were significant, planned contrasts were used 
to determine which points differed from baseline. Significant treatment effects and time 
by treatment interactions were followed up with post hoc paired t-tests.  Treatment 
differences for exercise duration, thermal sensation, thermal comfort, and lactates were 
determined by paired t-tests.  
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For each subject, postexercise values for gene expression measures were 
normalized to baseline values (1.00=baseline).  Metabolite-detecting (ASIC1, ASIC3, 
P2X4, TRPV1, and TRPV4), immunologic (IL-6, IL-10, and TLR4), adrenergic 
(ADα2A, ADα2C, ADβ1, and ADβ2), and indolamine (HTR1D and DRD4) mRNAs 
were examined using 2 (treatment) x 5 (time) RM ANOVAs with planned contrasts to 
evaluate time and treatment effects and time by treatment interactions.  Postexercise 
ratings of physical fatigue and pain were analyzed using RM ANOVAs. All data were 
presented as means and standard deviations, with significance set at α˂0.05. 
 
 Results 
Time trial physiological and perceptual responses are shown in Table 3.1. Peak 
Tcore was significantly higher during exercise in the heat (HT; 39.2 vs 38.3 °C), and 
significantly higher ratings for thermal comfort (more discomfort) and thermal sensation 
(hotter) were reported during HT (p<0.001). Compared to AT, HT resulted in 
significantly longer exercise duration (79 vs 75 min) and higher RPE (18.4 vs 17.4) 
respectively, while average power was significantly lower (157 vs 187 W) (p<0.01).  
Postexercise lactate measurements were significantly higher following the AT trial 
compared to HT (8.8 vs 6.4 and 6.6 vs 4.2 mmol L-1, at 1 and 5 minutes postexercise 
(p<0.01, Table 3.1).  
Significant overall time effects across AT and HT trials were seen for Tcore, 
power, heart rate, and RPE (F(2.4, 42) > 9.7, p<0.001, Figure 3.1). For Tcore, a significant 
treatment (AT vs HT) by time interaction was noted (F(2.3, 44) = 7.8, p=0.001), with 
between-trial differences observed from 25 to 40 km (Figure 3.1, panel A). Significant 
63 
 
treatment (F(1,19) = 33, p<0.001) and treatment by time interactions (F(3,58) = 2.9, 
p=0.038) were evident for power output, with significant between-trial differences 
observed from 10 to 35 km of exercise (Figure 3.1, panel B). Similarly, a significant 
treatment effect (F(1,18) = 20.1, p<0.001) was evident for RPE, with significant between-
trial differences seen from 20 to 40 km (Figure 3.1, panel D). Heart rate responses during 
AT and HT trials did not differ (Figure 3.1, panel C). 
  Perceptions of physical fatigue and pain increased significantly across both AT 
and HT, from 5 km to the end of the trials (F(2.3, 41) > 42, p<0.001, Figure 3.2, panels A 
and B, respectively).  Additionally, significant time effects were observed for 
postexercise physical fatigue and pain ratings (F(4,64) > 7, p<0.001). Physical fatigue was 
significantly higher at 0.5, 8 and 24 hours postexercise, and pain remained significantly 
elevated at 0.5 and 8 hours postexercise (p<.005, Figure 3.2, panels C and D). There were 
no treatment differences (AT vs HT) for perceptions of physical fatigue or pain during or 
after the trials.   
 
 
Gene Expression Changes 
 
Metabolite-detecting receptors.  There were no significant overall treatment or 
treatment by time interactions for any metabolite-detecting receptor mRNA (Figure 3.3). 
Significant overall time effects across AT and HT trials were noted for ASIC3, P2X4, 
TRPV1, and TRPV4 (F(4,64) > 7.5, p < 0.001), but not for ASIC1 (F(4,64) = 3.1, p = 0.054). 
Planned contrasts comparing postexercise time points to baseline indicated that ASIC3 
and P2X4 mRNA levels were significantly decreased at 0.5 and 8 hours postexercise (p < 
0.001). TRPV1 mRNA levels were significantly reduced at all postexercise time points (p 
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< 0.001), while TRPV4 was significantly lower than baseline only at 8 hours postexercise 
(p < 0.001). 
Adrenergic and indolamine receptors.  For all adrenergic receptor mRNAs, 
overall treatment and treatment by time interactions were not statistically significant 
(Figure 3.4). However, overall time effects were significant for all adrenergic receptors 
across both AT and HT trials (F(4,64) > 6.4, p < 0.001, Figure 3.4).  Contrasts indicated 
that adrenergic α2A, α2C, and β1 mRNA expression was significantly higher at 0.5 hours 
following the time trials (p < 0.006), with α2C and β1 remaining elevated at 8 hours 
postexercise (p < 0.001).  Finally, β2 mRNA significantly decreased at 0.5 and 24 hours 
following exercise (p < 0.007).   
For serotonin (HTR1D) and dopamine (DRD4) receptor mRNA, a significant 
overall time effect was observed (F(4,64) > 9.3, p˂0.001, Figure 3.5), but treatment and 
treatment by time effects were not significant.  Following exercise, HTR1D mRNA 
expression was significantly higher at 0.5- and 8-hour time points (p<0.001).  DRD4 
mRNA was significantly decreased at 0.5, 8, and 24 hours postexercise (p < 0.05). The 
treatment main effect for DRD4 approached statistical significance (F(1,16) = 4.4, p = 
.054), and it appears that DRD4 decreases tended to be more pronounced following HT.  
Immune receptors and cytokines.  Changes in immune gene mRNA after both 
trials are presented in Figure 3.6. For TLR4, significant time (F(4,64) = 14.8, p < 0.001) 
and treatment by time (F(4,64) = 4.0, p = 0.025) effects were observed. Contrasts indicated 
that TLR4 expression was significantly decreased at 0.5 and 8 hours following AT and 
HT; however, TLR4 levels remained decreased at 24 and 48 hours after HT but had 
returned to baseline at these time points after AT (p < 0.001). A significant overall time 
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effect was observed for IL-10 (F(4,64) = 10.7, p < 0.001), with contrasts indicating 
significant increases at 8 and 24 hours postexercise across both groups (p < 0.01). For IL-
6, the only significant main effect observed was for treatment (F(1,16) = 6.1, p = 0.026), 
indicating higher IL-6 levels for HT across all postexercise time points.    
 
 Discussion 
As has been previously documented, time trial performance during heat stress 
(HT) was significantly slower than during ambient conditions (AT) (42, 46, 49, 54, 56).  
Power output during HT was significantly lower than AT beginning at 10k into the trial, 
well before differences in core temperature were evident (beginning at 25k, Figure 3.1) 
(46). This suggests that the drive to reduce exercise intensity was not immediately caused 
by core temperature increases (brain thermoreceptor activation) but may have been 
mediated, at least in part, by thermoreceptors in the skin and/or muscle or by changes in 
cardiovascular function (42, 46).  It is also possible that the reduced power observed 
during HT may have been due to a change in pacing strategy in anticipation of challenges 
associated with heat stress, as has been demonstrated before (49). Interestingly, between-
trial differences in power were absent during the final sprint, indicating the ability to 
override sensory fatigue signals when the knowledge that the end of the trial is near (38). 
Although we hypothesized that time trial performance during heat stress would 
produce greater fatigue sensations, subjective ratings of physical fatigue and pain 
increased similarly during and after both trials; however, rating of perceived exertion 
(RPE) increased more over the course of HT (see Figure 3.2). Previous research has 
shown that the faster rate of change in RPE observed during heat stress was closely 
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related to pacing strategy (15). Our data are consistent with this observation. Thus, the 
cyclists presumably adjust their pace to achieve the same sensory fatigue level in both 
conditions, sacrificing their power (and therefore their performance). Remarkably the 
cyclists recognize increasing effort in the HT condition, suggesting that motor command 
to activate the working muscles is more difficult to generate in this condition, 
independent of the amount of sensory fatigue the cyclists perceive (33). It is possible that 
RPE is influenced by thermal sensation and discomfort, which were both significantly 
higher during HT. 
While there has been much research focused on causes of fatigue during exercise, 
there has been relatively little attention to postexercise fatigue, which can represent 
normal recovery processes or, in some clinical populations, may indicate pathology.  In 
this study, both trials resulted in similar postexercise increases in physical fatigue and 
pain ratings, lasting 8 hours after exercise. These perceptual responses suggest that 
overall work produced during an exercise trial does not completely explain postexercise 
responses, as HT power output was significantly lower.  
 
Gene Expression Following AT and HT Trials 
We expected that the addition of heat stress would produce greater sensory fatigue 
perception during and after exercise; however, HT and AT produced similar fatigue 
perceptions. The lack of difference in fatigue ratings matches the general lack of 






During exercise, Group III/IV afferents have been implicated in contributing to 
the decline in motor command and subsequent decrease in power (1-3).  Researchers in 
our group have determined that ASIC, P2X, and TRPV receptors, present on afferent 
fibers innervating skeletal muscle, may be responsible for detecting combinations of 
metabolites (H+, lactate, and ATP).  Signaling from these afferent neurons to the brain is 
then interpreted as fatigue and/or pain (29).  In combination with adrenergic, 
immunologic, and other receptors, changes in metabolite-detecting receptors may 
contribute to an increased fatigue sensation at rest for an extended period following 
vigorous exercise (30). 
In the present study, both trials resulted in decreases in metabolite-detecting 
receptor mRNA at 0.5 and 8 hours postexercise, that, except for TRPV1, returned to 
baseline levels by 48 hours postexercise. These results are in strong contrast to 
postexercise responses observed in patients with pathologic fatigue, who show sustained 
increases in these markers after only 25 minutes of moderate exercise (70% of predicted 
max heart rate) (28, 30). In those studies, controls demonstrated very small (if any) 
decreases in the mRNA of these receptors following the 24 minutes of moderate exercise. 
The postexercise decreases in metabolite-detecting receptor mRNAs observed in 
the present study may represent signaling to decrease metabolite-detecting receptor 
sensitivity in an attempt to reduce the afferent signal following exercise. In contrast, 
patients with chronic fatigue syndrome (CFS) experience severe postexercise fatigue 
perception in conjunction with amplified metabolite-detecting receptor mRNA expression 
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during the same period; thus, the receptors may have increased fatigue and pain 
sensitivity for up to 48 hours after exercise in these patients  (59).   
We hypothesized that after HT, there would be an increase in TRPV, P2X, and 
ASIC receptor mRNA, because TRPV receptors respond to heat and also influence the 
sensitivity of P2X and ASICs (6, 11).  Interestingly, higher postexercise lactate levels 
following AT did not result in any greater change in metabolite-detecting mRNAs 
compared to HT even though lactate is one of the essential metabolites that help signal 
muscle fatigue and pain (47). If heat is one of the metabolites that contributes to sensory 
muscle fatigue, it appears that in both trials cyclists chose work rates that produced very 
similar metabolite loads, leading to similar sensory fatigue levels in both the AT and HT 
trials.  This concept is also supported by the similar heart rate in both trials. These 
cyclists chose to match the sensory perception of fatigue, rather than attempt to match the 
performance speed. They apparently did this even in the face of slightly increased 
perceived exertion. Thus, it appears, at least for this sample of cyclists, that maintaining a 
certain level of sensory fatigue is more important than maintaining either perceived 
exertion or performance speed. 
The results of this study would likely have been different if we had matched the 
work rates between the two trials, rather than matching the participants’ effort.  With this 
paradigm, we may have seen an increased response of genes to the exercise in the heat as 






The adrenergic receptors alpha-2a, alpha-2c, and β2 are important in the 
regulation of blood flow. β2 receptors are also important in the exercise training 
response, as their activation enhances muscle oxidative and anaerobic metabolism (51). 
These receptors can co-localize with ASIC and P2X and thereby directly influence the 
sensitivity of these metabolite-detecting receptors (30). The observed significant 
increases in alpha-2C, alpha-2A, and β1 receptor expression following both time trials 
may have increased the sensitivity of metabolite-detecting receptors, thus contributing to 
fatigue sensations persisting after exercise. It is also possible that the changes in 
expression of alpha and beta adrenergics were a cause of or a response to decreased blood 
flow at rest (18).  In this case, if the quantity of adrenergic α2-receptors is increased in 
muscle blood vessels, just as in the leukocytes, there may be an increased resting 
vasoconstriction. The decreased muscle blood flow may be enhanced by a decrease in β2 
receptor expression.  In skeletal muscle, previous research has demonstrated that the β2 
receptor is the primary β-adrenoceptor controlling blood flow (22).  Thus, the increased 
vasoconstriction from the increase in alpha receptors, coupled with the decreased 
vasodilation from the β2 receptors, may lead to an increased resting metabolite load. The 
combination of increased metabolites and an increased sensitivity of the afferent nerve 
may lead to an increased sensation of fatigue postexercise.  
 
Indolamine Receptors 
Serotonin and dopamine also play a role in fatigue, particularly in conjunction 
with heat stress (49). Activation of the dopaminergic system is necessary to perform 
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exercise. Further, pharmacologic manipulation of dopamine levels via the dopamine 
reuptake inhibitor bupropion resulted in improved endurance performance (25, 58). 
Conversely, elevated levels of serotonin are associated with decreased motivation (11). 
During sustained aerobic exercise, serotonin levels peak at the point of fatigue. In the 
present study, we observed significant decreases in transcription of the dopamine receptor 
DRD4 at 0.5, 8, and 24 hours following exercise. Significant postexercise increases in 
transcription for the serotonin receptor HTRD1 were observed following both time trial 
conditions. This may be in response to the increased blood serotonin levels that are seen 
during exercise (7, 41). Increased serotonin in the periphery may increase the afferent 
signal during and following exercise.  Previously, it has been shown that serotonin 
activates the 5-HT receptor on afferent nerves leading to an increased firing rate (53).  
There may also be an increase in 5-HT receptors in the brain following exercise, 
increasing the sensitivity of the brain to endogenous serotonin (8).  
 
Immune Function in Fatigue 
For these genes, the only postexercise difference between the AT and HT 
treatments was increased expression of IL-6 in the HT group.  Unlike previous research 
that utilized a less intense exercise protocol (32), we found an increase in IL-6 mRNA 
postexercise  These differences may be due to utilization of more intense exercise as well 
as the thermal challenge.  The increase in IL-6 mRNA may contribute to increases in 
circulating IL-6, much of which is released directly from the muscle (52).  IL-6 may play 
a role in lipolysis, fat oxidation, and insulin-mediated glucose disposal (44) as well as an 
anti-inflammatory role, decreasing the amount of inflammatory TNF-α released into 
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circulation (45).  The increase in IL-6 mRNA following exercise in the heat, but not 
ambient conditions, suggests that there may be increased inflammation following 
exercise in the heat.  In addition, IL-6 has been associated with pain in a number of 
chronic conditions, and may play a direct role in increasing fatigue and pain sensations 
(17).  
Heat shock proteins (HSPs), in particularly HSP70, are increased following 
vigorous activity (34).  One way in which HSPs work is by binding to TLR4, causing an 
increase in NF-κB activation (5).  NF-κB is a pro-inflammatory transcription factor that 
may play a role in chronic inflammatory diseases (9).  This study found an approximately 
1.5-fold increase in TLR4 mRNA.  If this increase in TLR4 mRNA leads to an increase 
in TLR4 protein, an increased postexercise inflammatory response would result. 
Interestingly, following HT the TLR4 response remained elevated above baseline at 24 
and 48 hours postexercise, while values normalized after AT during this period. This 
suggests that heat stress may produce a longer lasting postexercise inflammatory 
stimulus.   
Following strenuous exercise, plasma anti-inflammatory cytokine IL10 levels 
have been shown to increase by as much as 27-fold (43), perhaps to counteract the 
concurrent large increases in inflammatory cytokine levels.  However, this study found an 
initial 10% decrease in IL10 receptor mRNA following exercise at ambient temperatures 
followed by a 1.5-fold increase 8 hours after both AT and HT.  Previously, it has been 
shown that IL10-deficient mice had increased levels of fatigue as compared to wild-type 
mice (27). In the same way, this initial decrease in IL10 receptor mRNA may contribute 
to the increased postexercise fatigue.  By 8 hours after exercise, IL10 receptor mRNA 
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levels increased, perhaps restoring the sensitivity of the body to the anti-inflammatory 
cytokine, reducing inflammation and fatigue levels.  The sum total of an increase in 
TLR4 mRNA and an initial decrease in IL-10 should be an increased inflammatory 
response following exercise, perhaps leading to an increased fatigue response.  By 8 
hours after exercise, the increase in IL-10 mRNA could mediate decreased inflammation 
and fatigue sensations.  
 
Methodological Qualifications 
A limitation of this study is that gene expression was assessed in leukocytes and 
may not represent changes in brain, muscle or other tissues. In addition, it is unclear how 
changes in gene expression would affect protein synthesis associated with any of the 
genes under study. Future studies should determine the relationship between changes in 
mRNA and the effect on protein synthesis. 
 
Conclusions 
The two time trials under AT and HT conditions produced similar and significant 
increases in fatigue, effort, and pain perceptions during and following exercise, despite 
the fact that significantly less work was produced during HT. Although the AT resulted 
in significantly higher postexercise lactate levels, changes in metabolite-detecting 
mRNAs were the same for both trials. This suggests that heat may inhibit exercise 
performance much like other metabolites, possibly due to its effects on TRP expression,  
increasing the overall afferent signal via group III and IV afferent during exercise (37), 
causing decreased motor command and central motor drive (55) leading to the observed 
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decreased power output.  The increase in serotonin and the adrenergic receptors along 
with the decrease in metabolite-detecting receptors and dopamine may play a pivotal role 
in the fatigue that occurs in many individuals following exercise, possibly persisting for 
several days. 
Understanding how exercise affects gene expression may lead to a better 
understanding of why athletes, healthy individuals, and even diseased populations 
perceive fatigue differently before, during, and after exercise, and how fatigue perception 
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Table 3.1. Mean physiological and perceptual responses to time trials during ambient 
(AT) and heat-stressed (HT) time trials.  
 AT HT p-value 
Physiological Responses    
Time (min) 75.2 ± 6.58 79.0 ± 7.20 0.002 
Power (W) 187 ± 40.3 157 ± 32.3 ˂0.001 
Heart Rate (bpm) 164 ± 15.7 165 ± 15.7 0.697 
Lactate – 1min post-ex (mmol·L-
1) 
8.8 ± 3.2 6.4 ± 1.7 0.002 
Lactate – 5min post-ex (mmol·L-
1) 
6.6 ± 2.7 4.2 ± 1.5 0.001 
Perceptual Responses     
RPE (6-20) 15.5 ± 1.46 16.4 ± 1.29 0.004 
Physical Fatigue (0-100) * 45 ± 21.7 51 ± 22.4 0.311 
Pain and Soreness (0-100)* 34 ± 22.9 36 ± 24.4 0.730 
Thermal Comfort 2.3 ± 0.68 3.6 ± 0.42 <0.001 
Thermal Sensation 5.0 ± 0.93 7.0 ± 0.41 <0.001 
Values are mean ± SD.  AT = Ambient Time Trial (21 °C); HT = Heat Time Trial (35 
°C)  






Figure 3.1. Groups means (± SD) for core temperature (panel A), power (panel B), heart 
rate (panel C), and RPE (panel D) at 5 km intervals during ambient (AT) and heat-
stressed (HT) time trials. Significant overall time effects were noted for each of these 
variables, p<0.001 with significant increases observed from 5 km to the end of the trials. 
For core temperature, a significant treatment by time interaction was noted, p<0.001, with 
significantly greater increases observed during HT after 25 km. Both treatment and 
treatment by time effects were significant for power (p<0.005), with treatment 
differences evident between 10 and 35 km. There were no treatment differences for heart 
rate. 
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Figure 3.2. Ratings of physical fatigue (PF) during time trial exercise and recovery 
(panels A and B) during ambient (AT) and heat (HT) trials. Ratings for pain are depicted 
in panels C and D. Significant time effects were noted for both variables during exercise 
and postexercise periods, p<0.001. Treatment (AT vs HT) effects were nonsignificant.  




















































Figure 3.3. Metabolite-detecting receptor gene expression for ambient (AT) and heat 
(HT) trials expressed as fold changes relative to baseline (1.0). Values are mean ± SD 
*  indicates significant difference from baseline across both trials, p<0.05 







































Figure 3.4. Adrenergic receptor gene expression for ambient (AT) and heat (HT) trials 
expressed as fold changes relative to baseline (1.0). Values are mean ± SD 
*  indicates significant difference from baseline across both trials, p<0.05; 



































Figure 3.5. Indolamine receptor gene expression for ambient (AT) and heat (HT) trials 
expressed as fold changes relative to baseline (1.0).  Values are mean ± SD 
*  indicates significant difference from baseline across both trials, p<0.05 







































Figure 3.6. Immune function gene expression for ambient (AT) and heat (HT) trials 
expressed as fold changes relative to baseline (1.0).  Values are mean ± SD 
* indicates significant difference from baseline across both trials, p<0.05 
† indicates significant treatment effect across all time points, p<0.05 







































Fatigue is a complex and difficult phenomenon to characterize.  Much of the 
current research has focused on the decrease in force-generating capacity of the muscle 
and whether fatigue is central or peripheral in nature.  However, since the early 1900s 
when Mosso described fatigue, including the sensation, or perception, of fatigue as an 
important component (11), this component of fatigue has been ignored by researchers.  
Therefore, the overarching purpose of these studies was to examine the perceived 
sensation of fatigue for several days following exercise and the gene expression 
responses to the same exercise.  It was initially hypothesized that strenuous exercise 
would cause an increase in metabolite-detecting mRNA, similar to the increases seen in 
chronic fatigue syndrome (CFS) (6, 10). 
Because these particular studies had their start in the CFS literature (6, 10, 12, 13, 
20, 21), we first wanted to examine how a graded exercise test and a time trial differed in 
both perceived fatigue and gene expression.  We also wanted to explore how the 
additional stressor of increased temperature would affect perceived fatigue and gene 
expression.  We found that a normal gene expression response to exercise in a healthy 
population consisted of a decrease in metabolite detecting genes (ASIC1/3, P2X4, and 
TRPV1/4), dopamine, IL-10, and adrenergic β2 as well as an increase in adrenergic genes 
(adrenergic α2a/c and adrenergic β1), serotonin, IL-6, and TLR4.  The magnitudes of 
these changes were affected by a combination of the intensity and duration of the 
exercise.  The changes in gene expression that occurred were larger following the time 
trial in ambient conditions than the graded exercise test, though the changes following the 
ambient time trial were similar to the time trial in the heat.  Even though exercise 
intensity was decreased during exercise in the heat, as evidenced by decreases in lactate 
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levels during exercise as well as postexercise, suggesting a decreased metabolite load, the 
metabolite load and subsequent afferent signal may actually be the same between these 
trials if heat is considered an additional metabolite, in addition to H+ ions, lactate, and 
ATP.  This suggests that the metabolite load, and subsequent afferent signal, is important 
in regulating the perceived effort level and subsequent power output during the time trial 
(19).   
When normal gene expression following exercise that causes a prolonged 
sensation of fatigue in healthy individuals is compared to a disease that exhibits abnormal 
pain or fatigue for several days following mild exercise, such as chronic fatigue 
syndrome or fibromyalgia, we found that the diseased response was vastly different than 
the healthy response (7, 10).  This suggests that there is an abnormal response to exercise 
by individuals who have these diseases, and it is possible to differentiate and diagnose 
these diseases using gene expression.  Further, it may be possible to use gene expression 
to determine the underlying causes of these diseases, perhaps allowing future treatment 
opportunities that address these different gene expression responses. 
The metabolite-detecting genes exhibited general decreases following each of the 
trials, irrespective of the length, intensity, or temperature of the trial.  The smallest 
decreases in gene expression followed the GXT while the longest lasting decrease 
followed the time trial in the heat (HT).  Because of this, it follows that the changes in 
gene expression may be related to work.  The smallest gene expression changes occurred 
following the exercise trial in which the least work occurred.  The decrease following 
each of these trials may represent a normal, adaptive response to exercise (22) and an 
attempt to ‘reset’ the fatigue signal to return the afferent signal to baseline levels of 
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fatigue and pain. 
While much of the pain and fatigue response is mediated through the metabolite-
detecting ASIC, P2X, and TRPV receptors (8), heat may also enhance the fatigue signal 
from any given level of metabolites by activating the TRPV receptors (1, 3).  The length 
of exercise may also play a role in the size of the response, as the duration of activation 
enhances the afferent signal during exercise.  Even though the metabolite levels were 
decreased during the 40k time trial in ambient conditions as compared to the graded 
exercise test, the changes in gene expression were much larger following the 40k time 
trial.  This may suggest that long durations of exercise may sensitize these metabolite 
detecting receptors, increasing the afferent signal, and thus increasing the sensation of 
fatigue during mild, prolonged exercise. 
The majority of the adrenergic receptors exhibited pronounced increases in 
mRNA gene expression following exercise, with the one exception being adrenergic β2, 
which decreased following both time trials, but not GXT.  Adrenergic receptors may 
influence fatigue in several different ways.  Adrenergic receptors, particularly β-
adrenergic receptors, may directly influence the sensitivity of the sensory afferents, 
increasing the signal sent by the metabolite detecting neurons (9).  Not only may 
postexercise sensitivity of the afferents be affected, but blood flow may be decreased by 
activation of the α-adrenergics within the blood vessels (5), leading to a decrease in 
arterial radius, increasing the concentration of metabolites and subsequent afferent signal. 
Serotonin and dopamine have long been suspected of playing a role in central 
fatigue during exercise.  The results from these studies also suggest that they may 
contribute to playing a role during long-term, postexercise fatigue.  The large increase in 
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mRNA for serotonin following exercise may increase the fatigue levels felt during the 
days following exercise.  When the serotonin receptor was activated in rats, the afferent 
signal was increased (18).  Dopamine has been shown to inhibit the depolarization of the 
afferent nerve when activated; thus, a decrease in dopamine mRNA may decrease the 
inhibitory affect, leading to an increased perception of fatigue (2, 16).  Thus, the 
concurrent increase in serotonin and decrease in dopamine mRNA may combine to 
accentuate the afferent signal, contributing to the increased perception of fatigue 
following exercise. 
The immune system may also play a role in the fatigue sensation following 
exercise, as there appears to be an inflammatory response with an increase in TLR4 and a 
decrease in IL-10.  IL-6, in particular, has been associated with pain in chronic 
conditions, and may also directly influence fatigue sensations (4).  IL-6 may also play a 
role in fat oxidation, lipolysis, and glucose disposal, particularly after exercise in the heat, 
suggesting a prolonged energy need, and perhaps indirectly reflecting an enhanced 
fatigue sensation (14). 
One of the main concerns with any gene expression study is trying to determine 
the cause for the change in gene expression and what subsequently happens to the 
underlying protein levels.  Gene expression is not necessarily directly linked to protein 
levels as gene expression may increase to restore a decrease in protein levels, such as 
when proteins are utilized and lost.  Gene expression may also increase in order to 
increase protein expression, perhaps to attempt to restore homeostasis within the body, 
such as a gene involved with blood flow trying to increase blood flow and subsequently 
decrease the metabolic milieu following exercise. 
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Future studies with gene expression and fatigue are needed to examine the effects 
of abnormal fatigue within otherwise healthy, trained individuals.  This may be able to be 
accomplished by examining the effects of “overtraining” or perhaps the less severe, 
initial stages of overtraining – overreaching.  Examining the beginning effects of 
abnormal fatigue such as overreaching may allow a better understanding of abnormal 
fatigue in diseased individuals, perhaps allowing an understanding of the causes of this 
fatigue.  Recent research has more clearly linked the metabolites produced from exercise 
with the sensations of fatigue and soreness associated with exercise (15).  A response to 
this article has also questioned whether the “no pain, no gain” adage of exercise applies 
to these receptors in the adaptations that follow (17).  In order to better understand the 
adaptation to exercise in these metabolite detecting receptors, it is necessary to do a 
training study to determine the changes in baseline metabolite-detecting receptors as well 
as to determine whether the exercise-induced gene expression differs after training.  It is 
also necessary to further examine intensity, duration, and temperature effects.  This can 
be done by holding intensity or duration constant, and examining gene expression effects 
while exercising at 3 different intensities or durations.  Temperature should also be 
further examined by holding intensity and duration constant while only changing the 
temperature in which exercise is performed.  Finally, it is necessary to examine how 
changes in gene expression ultimately affect subsequent protein expression. 
 In conclusion, the sensation of fatigue following exercise, as well as the central 
and peripheral fatigue observed during exercise, is likely caused in part by a combination 
of changes in each of the systems observed.  It is more than likely not just one system 
that causes the increase in fatigue observed following exercise.  Also, the changes 
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observed following exercise seem to be enhanced when exercise is performed at a high 
intensity for a longer duration, such as that seen during a time trial, though heat does not 
seem to further enhance the gene expression, possibly due to a decreased intensity during 
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